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ABSTRACT
Developing Artificial Intelligence tools to investigate the phenotypes
and correlates of Chronic Kidney Disease patients in West Virginia
Marzieh Amiri Shahbazi

Chronic kidney disease (CKD) is responsible for disrupting the lives of 37 million people
just in the USA, which is about 1 in 7 adults. CKD results in a gradual loss of kidney function
over time. Sometimes CKD doesn’t produce any significant symptoms until it reaches an
advanced stage. On the other hand, acute kidney injury (AKI) accounts for a sudden decline
in the kidney’s function. As a result, the kidneys fail to filter waste materials from the blood
and cause an increase in blood pressure. High blood pressure can cause heart disease and,
in the long-term, induce CKD. Literature to date says AKI leads to long-term adverse kidney
outcomes and linked to CKD. AKI diagnosis, its severity, treatment, and recovery process
have a major impact on the likelihood of a future diagnosis of CKD. This research attempts
to understand the patient’s trajectory toward developing CKD after AKI diagnosis, key triggers contributing to this trajectory and ultimately develop an Artificial intelligence-based
prognosis tool. To comprehend the role of AKI and previous hospitalization in the progress of
CKD, various cohorts of CKD patients are created: i) AKI after hospitalization before CKD ii)
Random AKI before CKD, and iii) No AKI before CKD. Prior comorbidities, medications, lab
results, and pertinent procedures are considered, and for each cohort of patients, the most
prevalent phenotypes are identified. The patient cohorts required for this analysis are generated from CKD patients residing in West Virginia. The data is provided by TriNetx, a global
network platform. K-means clustering and the latent class analysis (LCA) approach is used
to identify and group the phenotypes of CKD for each cohort. The high-risk patient groups
generated by the clustering algorithms are compared with each other. These results will help
clinicians to understand the risk factors of CKD and the overall trajectory of the development
of CKD. This research suggests that a single method of care does not work for all patients
since phenotypes vary for distinct groups of patients and categorizing patients into distinct
groups allows for the allocation of different resources and strategies for the care of different groups of patients. From this research, it is evident that patients’ risk profiles change
over the years before developing CKD. There are also similarities as well as differences across
the cohorts for each year, which suggests that CKD risk factors may be linked to prior AKI,
hospitalization, or inpatient care.
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1 Introduction
1.1

Overview

The primary function of the kidneys is to remove excess water and waste from blood to produce urine. The kidneys balance the salts and minerals that circulate in the blood, such as
calcium, phosphorus, sodium, and potassium, to keep the body functioning properly. Additionally, the kidneys produce hormones that maintain bone density, create red blood cells,
and aid in blood pressure regulation [1].
Acute Kidney Injury (AKI) also known as acute kidney failure or renal failure, occurs when
the kidney suddenly fails to perform its function and doesn’t filter waste from the blood[2].
Consequently, waste products in the blood increase dramatically and cause high blood pressure and injure the heart. It can rapidly develop over a few days or weeks. To recover the
kidney from the injury, it is extremely important to identify the abnormal function of the kidney in time . However, there exists a lag in diagnosing the injury which makes the recovery
process more difficult[3].
AKI is common in adults over 60 years of age who have been hospitalized, especially for
critical illnesses or intensive care[4, 5]. Nearly 25% of hospitalized patients develop AKI after
being admitted. Low- and middle-income countries are where this disease is more prevalent.[6].
There are several reasons that could result in AKI. One of the major reasons is decreased
blood flow. Many diseases and conditions can reduce the blood flow in the kidney such as low
blood pressure (also known as hypo-tension) or shock, blood or fluid loss such as in bleeding
and severe diarrhea, heart attack, heart failure, and other conditions that affect the heart’s
ability to pump blood, overuse of some medicines (used to treat headaches, the flu, colds, and
other conditions by reducing swelling or reducing discomfort), significant allergic responses,
burns, an accident, major surgery, etc[1]. The second main factor is kidney damage brought
on by direct trauma, such as a sort of severe, hazardous infection, a form of cancer, blood
vessel inflammation, or an allergic reaction to specific kinds of medications. An obstruction
in the urinary system is the third cause.[4].
The symptoms of AKI include decreased urine output, swelling in the legs, ankles, and
around the eyes, difficulty breathing, weakness, nausea, confusion, and exhaustion, abnormal
heartbeat, chest pressure, or seizures and coma in severe cases. However, in some cases,
there are no symptoms at all and it’s diagnosed through lab tests. AKI diagnosis is based
on changes in serum creatinine and urine output(an increase in serum creatinine (SCr) or
a decrease in urine output (UO))[7–9].Tests such as blood urea nitrogen (BUN), fractional
excretion of sodium, and urine microscopy could be carried out to help clinicians determine
the severity and diagnose possible underlying cause of the AKI[10].
AKI has both short-term and long-term outcomes depending on the recovery success of
initial AKI . Initial AKI can be followed by a number of different recovery patterns, such as
1
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sustained AKI reversal, recurrence after full or partial recovery from the first episode, and AKI
without reversal. Depending on the patterns of healing, long-term outcomes varied greatly
amongst patients. Those with AKI, who relapsed or never recovered had longer hospital stays
and increased mortality in the nine months after the original AKI occurrence than patients
who fully recovered[6]. The patient may have comorbidities like diabetes, hypertension,
chronic kidney disease (CKD), cardiovascular disease (CVD), liver disease, lung disease, sepsis and surgery and exposure to nephrotoxic drugs[7]. Heart failure and sepsis are the most
important potential adverse outcomes of AKI because the sudden dysfunction of the kidney
dramatically increases the blood pressure, and high blood pressure causes heart failure[11].
One of the long-term outcomes of AKI is chronic kidney disease (CKD)[12]. CKD is a
gradual loss of kidney functions. Kidneys with chronic renal disease are harmed and unable
to filter blood as they should. Because the kidney damage occurs gradually over a long period
of time, the condition is referred to as ”chronic”. Wastes may accumulate in the body as a
result of this harm. Other health issues can also result from CKD[4].
Over time, renal disease frequently worsens and might result in kidney failure. Dialysis or
a kidney transplant are required for CKD patients to maintain their health after the kidney
failure.
Patients with CKD may not exhibit many symptoms or indicators in the early stages.
It’s possible that they won’t be diagnosed until it’s progressed to an advanced stage. They
can take action to save their kidneys as soon as they become aware that they have renal
disease. Other health issues, like heart disease, can also develop as a result of kidney disease.
A heart attack is more likely to occur in persons with kidney dysfunction. High blood pressure
can work as both the cause and the effect of renal disease. Kidney injury makes it hard to
maintain a healthy blood pressure. Furthermore, people with CKD are more prone to develop
a sudden change in kidney function as a result of a disease, accident, or medicine. So, AKI
can lead to CKD and CKD patients are more vulnerable to future AKI[7].
The diagram below depicts how AKI can progress to CKD and then back to AKI in the
long run.
Research has revealed that patients who fully recover from early AKI following surgical treatment have a comparable risk of CKD and long-term mortality to those who do not, hence
this study will concentrate on CKD as a long-term outcome of AKI[13].

1.2

Motivation

Rising number of CKD patients in recent years poses significant burden to the healthcare
systems in USA (CKD patients increased by 52.6% between 2002 and 2016[2]). It results in
damaged kidney over time and contributes to many other significant diseases such as high
blood pressure, heart disease, stroke, etc [14]. CKD is a silent disease and almost 9 out of
10 people do not know that they have CKD [3]. Given the significance of the kidneys to the
body and the fact that CKD gradually impairs kidney function while occasionally exhibiting
2
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Figure 1.1: Long-term consequences after AKI[7]

.

no symptoms, it is crucial to identify high-risk patients at an early stage. AKI increases the
likelihood of developing CKD and historically shows an association with CKD [15]. So, an
intervention just after the AKI occurrence can possibly mitigate the risk of CKD in long term.
To take action in this phase, a deeper comprehension of the AKI to CKD transition is required.
Common comorbidity increases the risk of CKD and makes it desirable to identify. Due to
the potential for an insidious progression of the disease, CKD is typically disregarded in the
clinic until it is severe, and this is another reason for the importance of CKD prediction.
The rising number of CKD patients, its related direct and indirect expenditures, as well
as the rising costs resulting from its severity, are what motivate our research to better understand how patient diagnosed with CKD after having a prior AKI. The cost of CKD has
an impact on society, caregivers, and patients. Identification, management, and treatment
of CKD are all included in the cost of care for CKD patients. Managing comorbidities including diabetes, hypertension, and heart disease is also a part of treating CKD, as they all
increase the cost of treatment. Patients’ and carers’ productivity is impacted. Patients’ productivity falls due to absences and overall inefficiency at work, whereas carers’ productivity
rises as a result of investing more time and effort in their charge. The time and money spent
by patients, carers, employers, and healthcare professionals also have an impact on society.[16].The CKD cost for non-dialysis patients is around $15,000 per patient for a one-year
care period.[17]. Therefore, the increasing frequency and progression of chronic kidney disease (CKD) raises questions about how to efficiently manage the financial burden it places
on patients, caregivers, and society. The societal costs of CKD and end-stage renal disease
are substantial and increases as the disease progresses. [16]. All of these impacts inspired
3
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us to investigate the AKI to CKD trajectory and understand the factors responsible for CKD.
Once the patients groups who are more vulnerable to CKD and their distinct characteristics
are identified, specific intervention strategies can be designed to reduce the risk of long term
CKD and associated complications.

1.3

Objectives of the research

The objectives of the research are as follows:
i. To develop different CKD cohorts for understanding the patient’s trajectory from the
onset of AKI toward CKD diagnosis.
ii. To develop clustering algorithms for creating several distinct patient groups with similar
characteristics across cohorts.
iii. To compare among cohorts across years to find out the similarities and dissimilarities in
terms of important clinical variables.

1.4

Research questions

The overarching theme of this research is to understand patient trajectory between AKI and
CKD as its long-term outcome. To understand the patient trajectory the thesis attempts to
answer the following research questions:
a) Is CKD more prevalent in patients with prior hospital induced AKI and compared to the
patients with no AKI?
b) Are there any differences between hospital induced AKI injury compared to the random
AKI injuries (who didn’t have an induced condition for the AKI prior to CKD and hospitalization) in long term CKD development?
c) What are the roles of prior comorbidities, medications, lab results and relevant procedures
in developing CKD?
d) What are the most prevalent phenotypes in different CKD patient groups?
e) Can we find similarities and dissimilarities in the phenotypes over a time period prior
CKD diagnosis?

4

2 Literature Review
The remainder of this thesis is organized as follows. Section 2 highlights the relevant works
in the literature. Section 3 describes the dataset, study design, and preparation of cohorts.
Section 4 illustrates the data mining methods and machine learning approaches that have
been utilized in this research. Section 5 discusses the results and conclusions.

2.1

Research domain

This review has been carried out using the papers available on PubMed Central (PMC), which
is a free full-text archive of biomedical and life sciences journal articles at the the United
States National Institute of Health’s National Library of Medicine(NIH/NLM). Google Scholar
is also used as an additional web search tool. The main emphasis is provided on the recent
works that discussed the possible association between AKI and CKD and their respective
phenotypes, and diagnosis. We also included papers where machine learning (ML) methods
and data mining algorithms are proposed to predict AKI risk variables and outcomes.

2.2

AKI, phenotypes, diagnosis and prediction

AKI occurs when the kidney function suddenly decreases. It will be followed by an increase
in serum creatinine or a decrease in urine output[18]. It is one of the major reasons for patients’ mortality[19]. Identifying the phenotypes for AKI helps to identify the disease early
and reduce the threat of AKI. The phenotypes for AKI can be divided into two groups. One
is chronic phenotypes, which includes chronic kidney disease, chronic liver disease, congestive heart failure, hypertension, and atherosclerotic coronary vascular disease which all have
the same risk. The second one is acute risks, including low pH, nephrotoxin exposure, severe
infection/sepsis, mechanical ventilation, and anemia, where the first two poses the highest
level of risk, followed by the second two acute factors, and finally anemia has the lowest
risk among the acute phenotypes[19]. Different ML methods were used to predict AKI including logistic regression[19, 20] and k-nearest neighbors[18] that had the high accuracy in
prediction.

2.3

CKD, phenotypes, diagnosis and prediction

CKD results in a steady decline of the normal kidney activity and, as a result, destroys kidney
functionality in the long run. When the kidney fails completely, dialysis is needed for the
survival. This is a health burden. Around 1.4 million CKD patients in the world needs to
replace their renal. Apart from being painful, it is extremely expensive [21, 22]. It is diagnosed
at the advanced stages either by decline in estimated glomerular filtration rate (eGFR) and/or
the presence of significant albuminuria [23]. Individual’s genetics, age, race, gender, and
5
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family history are important phenotypes for CKD, also, smoking, obesity, hypertension, and
diabetes mellitus can also lead to CKD[22].
The most crucial variables for predicting the start and progression of early CKD in people
with diabetes were albuminuria and eGFR. The performance of prediction is only slightly enhanced by the addition of demographic, clinical, and other laboratory factors[24]. Different
methods have been used to predict CKD, like linear regression, generalized additive models,
Gaussian process regression, regression trees, and k-nearest neighbor for continuous outcomes. For binary outcomes, logistic regression, classification tree, support vector machine,
and k-nearest neighbor have been used[25].

2.4

AKI to CKD trajectory

Studies about CKD followed by AKI show that there is a substantial link between AKI and
CKD[7, 10, 26]. Patients with AKI have a 41-fold increased chance of developing CKD than
patients without the condition, and patients with prior AKI have a 28-fold higher chance of
developing advanced CKD than those without prior AKI[26]. The severity of the AKI before
the CKD also influences how severe it is thereafter. More severe CKD will occur after serious AKI. Moreover, experimental trail for AKI models confirms the statistical correlation and
provides insights on the molecular mechanisms by which AKI contributes to future CKD[27].
On sometimes, AKI cannot make a suitable or acceptable adjustment to the situation[10].
As a result, in this situation, CKD will worsen over time. Age, and comorbidities, among other
clinical variables, can also affect how CKD develops. If people who are more likely to undergo
late CKD progression can be identified early, further research is still needed to answer this
question. An important research goal is still to develop new treatments to reduce the risk of
CKD after AKI.
Effectiveness of model risk predictions following AKI, shows that 1 in 7 patients with AKI
have its side effects, and 1 in 3 AKI patients don’t fully recover before being released from
the hospital[28]. However, more study is needed to determine which AKI outcomes are more
likely to occur, when they are more likely to happen, and what may be done to minimize serious consequences in high-risk individuals. There is a gap for post-AKI patient follow-up that,
if filled, will reduce mortality, readmission, CKD, cardiovascular, and other AKI outcomes.

2.5

Methodology review

One of the key methods in data mining is clustering. In order to uncover the structure of the
data and hidden groups among the patients also, it can be helpful to categorize individuals
or patients based on their similarity in phenotypes. In general, the first stage in clustering
entails dividing up related data into groups that are similar to one another. The second phase
involves giving each group a name based on the similarities among classes and differences
6
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with other groups. As a result, care can be delivered in the various facets of the healthcare
industry more effectively and efficiently.
Data mining from clinical and diagnostic data is utilized in healthcare to come up with
early detection in this field.[29]. The vector quantization method, as one of the clustering
methods, has been used in healthcare to predict re-admissions in intensive medicine. The
algorithms used in the vector quantization method are k-means, k-medoids, and the K-means
obtained the best results. [30].
Clustering has been used in data mining even in an area where it didn’t work much due
to the presence of substantially skewed distribution like budget data. One of the area that
clustering in data mining had been used, is to identify costs changing in the end stage of
kidney disease who initiated hemodialysis. Clustering methods like, k-means CA and hierarchical CA, can be used in this area and seems they work good. It is important to note that
the k-means CA method works better for data with highly skewed[31].
Latent class analysis(LCA) and k-means clustering analysis were employed, as two clustering techniques to find complex patient profiles among people who take several medications. K-means and latent class analysis produced identical groupings based on the quantitative findings. It was discovered that complex patient profiles can be divided into various categories, which aids the healthcare system in managing treatment and allocating resources.[32].
Hierarchical cluster analysis (HCA) is another method for clustering that had been used
for complex patterns of concurrent medication use In order to categorize pharmaceutical
exposure [33]. HCA had been used to determine which strategy is most appropriate for a
certain sort of data, some studies compared the HCA method with methods from past studies
that used k-means and latent class analysis. The k-means method is suitable for quantitative
variables; however, it is only applicable to quantitative variables with interval scales, and it
is restricted in its applicability when dose volume information is missing because it is not
suitable for categorical variables. This approach employs a conventional vector of distance
toward the center. Latent class analysis, which is more flexible than the k-means method
is also more suited for variables of mixed scale types[34]. However, it needs data reduction
when we have a high number of variables. Some research points out that HCA is the best
clustering method for identifying high-risk exposure patterns. That is because HCA allows
flexible data reduction; it is good for categorical variables and longitudinal data; it can be used
for any type of variable; and it allows for the use of a custom distance metric. After HCA, the
optimal number of clusters needs to be identified, which was based on the dendrogram and
algorithms that automatically find the optimal number of clusters. Research shows that the
definition of risk can be improved by uncovering actual patterns of prescription use and can
be used to detect risks related to various exposure profiles for other drugs, and past analysis
has shown[35].
Numerous hierarchical clustering techniques exist. Every one has a distinct definition.
They discover that the points fit into each cluster in a unique fashion, although everything
7
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works well when clustering various kinds of data[36].
Determining the group of individuals with various chronic diseases who receive the major
portion of Medicare beneficiaries was another area where cluster-based techniques had been
used. Researches showed that one-third of adults who have three or more chronic conditions
are responsible for two-thirds of healthcare expenditures in the USA [37]. Agglomerative
hierarchical clustering as one of CA methods had been used and discovered that there is
within-group pattern between patients with multiple chronic disease. Patients with heart
failure and kidney disease makes up the majority of the group that spent almost one-fourth
of the total budget. Agglomerate hierarchical clustering approach is a preferred method for
two reasons. First, it doesn’t need a pre-assigned number of clusters. and the second one
is that clusters are mutually exclusive. This method starts with one single cluster, then they
divide it into smaller clusters with the most similarity. This nesting cluster helps the number
of clusters chosen by the statistical criteria at each step [38].
In general, clustering methods in healthcare can be divided into three methods: a) Partition based clustering which employs K-means and K-medoid to group n data points into
K classes. b) Hierarchical Clustering. This method can be classified as Agglomerative and
Divisive and finally c) Density based clustering method also play a very important role in
biomedical research because they are capable of handle any cluster of arbitrary shape [39].

2.6

Knowledge gap

Mostly previous literature selected their variables by medical selection only. However this
research has been carried out to utilize artificial intelligence tools for variable selection and
analyzing CKD risks in patient groups after AKI besides the medical selection.
We chose to use machine learning (ML) methods over more traditional techniques because
they are faster and more accurate when applied to large data sets.Additionally, it can be updated by passing time. On the other hand, ML can identify hidden patterns in the dataset
which traditional statistical methods cannot.
Also, we defined different cohorts of patients to consider the effects of multiple criteria on AKI
prior to CKD at the same time. For instance, one cohort has been designed to see whether any
patients who develop AKI after hospitalization can get CKD or not. In general, AKI-related
hospitalization has been considered. Another cohort considered AKI not related to hospitalization to find out how other factors can affect CKD. The last cohort is a control cohort. This
cohort controls the effects of AKI on CKD. Each cohort has been explained in more detail at
Part 3.4.
In general, it is important to understand how patients in cohorts with previous AKI are different from patients in another cohort without prior AKI in terms of different health characteristics.Comprehensive clustering-based patient profiling which is a novel method Implications
had been used in this research to help clinicians to understand the transition from AKI to
CKD better and how AKI groups are different from the control group. Also, it will help to
8
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understand early the patient trajectory or profiles from AKI to CKD health status.
Some other long term outcomes for AKI like cardiovascular disease has been considered and
investigated for its association with AKI but not CKD. As CKD is considered to be one of
the most distressful diseases for a patient and a major financial burden for the government,
identifying high-risk patients for CKD and then monitoring them to detect CKD at an early
stage is critically important and that is what this study is targeting to achieve.
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Research dataset

Data for this study was provided by TriNetX, a global network platform that has been used by
healthcare institutions practically everywhere in the world to gather historical patient data
and make use of this information collected from over 29 countries. TriNetX retrieves data
from the electronic health record (EHR), verifies its accuracy, and saves it in accordance with
a common format. This platform categorizes the data as belonging to the patient’s demographics, diagnosis, procedures, measurement of the lab results, prescribed drugs, and vital
signs. Patients with chronic kidney disease (CKD) in West Virginia, USA, were the subject
of this study. A total of 75033 CKD patients of various disease stages participated in the
study. 7696 of them experienced AKI in the three years prior to CKD, and all of them had
hospitalization/admission visits in the 90 days prior to AKI.

3.2

Study design and setting

This study considered the possibility of CKD after a maximum of five years following AKI.
This is due to the presumption that the patients’ features would significantly alter after three
to five years. We also focus on the patients who were hospitalized in the 90 days before AKI,
if they had AKI prior to CKD, to find a relationship between AKI and hospitalization too.

3.3

Data preparation

Data preparation is the most important part and the first step of data analysis. It accounts
for nearly 80 percent of the problems solved in this area. The goal of this part is to gather
relevant data to make sure analytic tools provide useful information and practical insights for
identifying phenotypes and finding hidden patterns in clinical data related to AKI and CKD.
In this section, we used several filtering, merging, and categorizing tools to find and analyze
the important variables and their effects on the study.
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Dataset
Sex

CKD patients in West Virginia
Male
Female

37073(%49.42)
37937(%0.50.58)

>60(years)
<60(years)

57581(%84)
11244(%16)
0.18-50/30.8(kg/m2)

Asian
Black or African American
Native Hawaiian or Other Pacific Islander
White
Unknown

104(%0.14)
2596(%3.46)
38(%0.05)
63512(%84.65)
8782(%11.7)

Age

BMI (range/mean)
Race

Table 3.1: Data details

3.3.1

Patients with CKD

To find out the start date when CKD was first diagnosed for a patient, we filtered data on the
diagnosis file based on the codes which start with ”N18”. This code is used for CKD patients
in the ICD-10-CM code system. The Diagnosis table contains the ”patient id,” a unique id for
each patient; the ”encounter id,” a unique id for each encounter; and The ”code system,” in
which the diagnosis is coded, encompasses ICD-9-CM and ICD-10-CM. The column ”Code”
is used to determine the type or name of the diagnosis, and ”date” is the date the diagnosis
was recorded, which we used as the CKD start date. There are several duplicates for each
unique patient. This file keeps all the diagnoses that are identified for an individual patient,
which includes different levels of CKD, AKI at different times, and the comorbidity available
for each patient. Due to these reasons, we face several duplicates in this file. The results from
this part are gathered in two different files. One is for CKD patients with different encounter
ids at different dates. That means a patient was admitted multiple times with the ICD-10
code of CKD. The second file includes a unique CKD patient ID with the date of the first
occurrence of the CKD.

3.3.2

Patients with and without AKI

Patients with CKD are at first divided into two groups: those who had AKI prior to CKD and
those who did not have AKI prior to CKD. To find the first cohort, we find all AKI patients
from the diagnosis file based on their codes that were saved by N17 for patients. This code
is based on the ICD-10 system code. In this cohort, where all AKI patients are included, the
first date or the smallest date is kept as the index date for the AKI (this is the date a patient
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identified for AKI), and all other duplicates are dropped from this file.
Then among these patients, those who got AKI ”prior” to CKD are considered in our study.
So, based on the index date for CKD (first occurrence of CKD) and the index date for AKI
(first occurrence of AKI), those whose index date for AKI is before the CKD diagnosis date
are filtered and kept as the AKI prior CKD cohort. To consider the second cohort, who are
patients that didn’t have AKI before CKD, we segregate the patients whom were at CKD
cohort but were not diagnosed for AKI prior CKD. This cohort is named as NO AKI prior
CKD. So now we have three cohorts: 1) AKI after hospitalization prior CKD, 2)AKI at rondom
prior CKD, and 3)No AKI prior CKD

3.3.3

Patients with AKI prior to three years of CKD

Cohort one is limited to patients who had AKI at most ”three years” prior to CKD. We chose
this timeline based on our literature review of the average time of CKD diagnosis after AKI.
AKI in CKD patients prior to three years was filtered based on the time between the index
dates and divided into two cohorts. If the time between the date diagnosed as CKD patients
and AKI patients is zero, we removed them, as they considered prevalent cases of AKI. We created the cohort with patients who had time difference of less or equal to three years between
CKD and AKI diagnosis dates.

3.3.4

In-patients hospitalized

We also need to know the patients who were hospitalized before being diagnosed with AKI,
as it is an important factor for developing hospital induced AKI and later leading to CKD.
Thus we must identify the hospitalized patients first.
Any interaction between a patient and a healthcare provider(s) for the purpose of delivering healthcare services or determining a patient’s health condition is referred to as an
encounter. Therefore, an encounter file must be created for each patient admitted as an inpatient to a hospital. There are many encounter categories, such as ambulatory (AMB), emergency (EMER), home health (HH), inpatient encounter (IMP), inpatient non-acute (NONAC),
observation (OBSENC), pre-admission (PRENC), short stay (SS), and virtual (VR), according
to the TriNetX data dictionary. These values are based on the ActEncounterCode value set
from HL7 version 3.
In-patients are classified in the encounter file as having the type ’IMP’ based on the
TriNerX data dictionary. Because our focus is on patients who were hospitalized 90 days
before developing AKI, we kept patients who had both AKI and CKD within three years of
each other and who had also been hospitalized within 90 days of developing AKI. To find
patients who had been hospitalized, we filtered patients with the type code ’IMP’.
We have five types of CKD patients. The first group includes patients whose diagnosis
time between AKI-CKD is zero; the second group, whose diagnosis time between AKI-CKD is
less than three years; and the third group, whose time between AKI-CKD is more than three
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years but less than five. The fourth group, which is beyond our study, is patients with a time
between AKI-CKD of more than five years. The last group are patients who never had AKI
before CKD.
In this research, we separately identified hospitalized patients for each of these groups to
consider phenotypes for patients in each group.

3.3.5

Medical procedures

In the medical field, a ”procedure” refers to the hierarchical actions doctors take to improve a
patient’s condition. It includes figuring out, evaluating, or diagnosing the parameters or condition of the patient; treating, resolving, or restoring function, for instance, through surgery
and physical therapy. Additionally, each activity and service that patients can receive from a
healthcare practitioner is given a CPT code, which is a number and saved for each patient’s
encounter in a procedure file.
In this study, admission visits that demonstrate the effectiveness of physicians should also
be taken into account for each patient, in addition to hospitalization, which demonstrates
the efficacy of healthcare providers and systems. As a result, we identified every patient who
had a CPT code in the procedure file. These codes cover all ”inpatient visits” with: hospital inpatient initial care; hospital inpatient subsequent care; hospital observation initial care;
hospital observation subsequent care; hospital observation per hour; hospital inpatient initial consult care; hospital inpatient initial care (between 8hrs to 24hrs) and discharge on the
same day; nursing facility inpatient initial care. It also covers ”outpatient visits” with: outpatient established office care; outpatient new to office care; outpatient consult care. ”Critical
care”: Critical care and ”Primary care centers”: Standard Office Visits, New Patient (comprehensive), New Patient (extensive), Established Patient, brief, Established patient (moderate),
Established patient (in-depth), Established patient (extensive).

3.4

Study cohorts

We are considering three cohorts of the patients in this study.
a) Cohort 1: AKI after hospitalization/inpatient visits (Those patients who had AKI within
90 days of any inpatient services), first occurrence of AKI had been chosen, those patients
who had AKI and CKD on the same date discarded in this group (time difference is 0),
those patients who developed AKI after 90 days of inpatient visit discarded and saved in
as a separate file. Three years is chosen for this cohort, as this group is with people who
have AKI after hospitalization, and we hypothesize that this impact can be measured up
to 3 years.
In this cohort, we want to see whether any patients develop AKI after hospital service, can
get CKD or not, and in general, AKI related to hospitalization.
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b) Cohort 2: AKI at random ,including AKI prior to 3 years of CKD and hospitalized beyond
90 days prior AKI and AKI prior 5 years of CKD who are not in cohort 1.
In this cohort, we want to consider AKI when it isn’t related to hospitalization. and to see
how other things can affect CKD.
c) Cohort 3: Non-AKI-patients in other word, AKI never occurred for these CKD patients.
This cohort is a control cohort, means that patients in this group did not have the disease
of interests (without AKI).
The goal is to compare these cohorts for different criteria such as phenotypes for patients in
each group in order to determine the impact of AKI, hospitalization, or admission visit on the
progression of AKI and CKD.
Figure 3.1 shows the details of each cohort and the inclusions and exclusions of the study.

3.5

Phenotypes profiling

Following are the five categories of factors that are most widely viewed as significant factors
for CKD and AKI in the literature:
i Diagnosis
ii Procedures
iii Lab results
iv Vitals
v Medications.
The phenotypes from each group, as listed above, considered, and the arbitrarily number of
variables selected from each. According to what we’ve seen in the literature, we looked at
the top 50 comorbidities, roughly 100 lab results and vitals, 100 procedures, and roughly 200
medications, which is how this type of data is normally provided. Therefore, the number
of codes changes based on the type of data we are analyzing. These figures were chosen
because they can more easily be translated into percentages and accurately reflect the bulk
of the population.
In this research, we choose the top 50 comorbidities based on both ICD-9 and ICD-10
codes. In between these 50 comorbidities, we have 16 groups which include similar codes.
The 16 groups are: hypertensive diseases, disorders of lipoprotein metabolism and other lipidemias, Type 2 diabetes mellitus, diseases of the blood and blood-forming organs, atrial fibrillation and flutter, chronic obstructive pulmonary disease, Heart failure, overweight and
obesity, abnormalities of breathing, Osteoarthritis , Hypothyroidism, Chronic ischemic heart
disease, Anxiety disorders, Pleural effusion, Gastro-esophageal reflux disease.
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CKD Patients
(N=75033)

Drop Dialyses
Prior to CKD
(N=855)

AKI Prior CKD

ALI Later CKD

CKD Never AKI

(N=21547)

(N=13351)

(N=39280)

Out of Study

Cohort 3

(N=13351)

(N=39280)

AKI Prior 3
Years CKD?

no

AKI Random

yes

Hospitalized 90
Days Prior to AKI?

no

AKI Prior 5
Years CKD?

yes

yes

Cohort 1

Cohort 2

(N=7442)

(N=6408)

no

Out of Study
(N=8551)

Figure 3.1: Flowchart of inclusion for the final study population
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From procedure we found top 100 codes which are more frequently present in the file.
For the lab results we select a threshold to separate the positive and negative patients.
We find all codes in the groups of: Urea nitrogen [mass/volume] in serum, plasma, or blood
in the range of 6.0-24.0, Alkaline phosphatase [enzymatic activity/volume] in Serum, Plasma,
or Blood in the range of 44-147, Protein concentration (mass/volume) in serum or plasma
in range of 6-8, Folate [mass/volume] in Serum, Plasma, or Blood in range of 6-10, Cobalamin (Vitamin B12) [mass/volume] in Serum, Plasma, or Blood in range of 200-900, Hepatitis
B virus surface Ab [Units/volume] in Serum for patients with value more than 12 for positive hep,Hemoglobin A1c/Hemoglobin.total in Blood with value more than 6.5 for positive
diabetes, White blood cell /Leukocytes [/volume] in Blood with value between 4.5 - 11, Bilirubin.total [Mass/volume] in Serum, Plasma or Blood value between 0.1 - 1.2, and for vital includes Heart rate by value between 60-80, body temperature(36.4-37.2 Celsius), body height,
body weight, BMI(18.5-24.9), blood pressure, systolic(120) and blood pressure, diastolic(80).
Finally for the medication, we found top 500 medication codes for CKD patients.
Other variables that were considered during this study were: heart rate, body temperature, body height, body weight, BMI, blood pressure(systolic) and blood pressure(diastolic)
which are from vital file.

3.6

Creating binary files

Final step in data preparation is generating binary variables for individual patients in each
cohort.
For each patient, we have around 1322 variables for cohort 1 and 1910 variables for cohorts
2 and 3, including: for each year, we considered 50 binary variables for the diagnosis; 100
binary variables for the procedures; 33 binary variables for the lab results and vital signs;
and 500 binary variables for the medications. For diagnosis and procedure variables, we took
into account whether each variable was positive (meaning a patient was diagnosed for any
commodity or had any procedure) in the first year following AKI, the second year following
AKI, or the third year following AKI. Consequently, for cohort 1, we end up with 150 variables
for the diagnosis (50 for year 1, 50 for year 2, and 50 for year 3), as well as 300 for the procedure
(100 for each year).
We have 33 variable for the lab results and vitals. which considered every three months
for three years in cohort 1 and five years For cohorts 2 and 3, As a result, for cohort 1, there
are 132 variables each year and 396 variables overall throughout the period of three years,
and 660 overall variables for cohorts 2 and 3.
For medication, we simply looked to see if a patient had taken any of the top 500 medications prior to CKD, three years for cohort 1, and five years for cohorts 2 and 3.
A binary row was produced for each patient. For example, if a patient in each cohort had a
diagnosis in the first year, second year, or third year, encountered any procedures in the first
year, second year, or third year, had abnormal results for lab tests in the first three months,
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second three months, and so on, or had taken any medication, we would insert 1 for the
intersection of the variable and patient, and 0 otherwise.

3.7

Adjusting for missing values

We were facing too many missing values in each cohort. They can be divided into three
groups:
1. Missing value in some periods
Patients in each cohort had been considered over several periods of time for each class of
variables. For instance, diagnosis and procedure variables are considered in three periods
for cohort 1 and five periods for cohorts 2 and 3, or lab results and vitals are considered in
12 periods for cohort 1 (each three months during three years) and 20 periods for cohorts
2 and 3, and medications are considered in one period of 3 years for cohort 1 and 5 years
for cohorts 2 and 3.
Before altering missing values for patients in this group, we considered to see if they were
related to labs and vitals. We examined whether the majority of the patient’s records
that were available were normal or abnormal. We filled in the missing values with 1 as
abnormal when patients were found to have a majority of abnormal lab results or vital
signs, and with 0 as normal when the majority of a patient’s records were discovered to
be normal. In all other cases, we set zero in place of any missing values for other classes
of variables.
For lab and vitals variables, there are three possible scenarios: first, patients who did not
test(NaN) ; second, patients who tested and received normal results(0) ; and third, patients
who tested and received abnormal results(1). However, for other variables, say medication,
patients took a medicine(1) or not(1), or had a comorbidity(1) or not(1). Because of this,
we only evaluated NaN in lab results and vital signs; otherwise, we interpreted missing
values as zero.
2. Missing values in some class of variables
In general, we are considering on five groups of variables (diagnosis, procedures, lab results, vitals, and medications). Some patients’ records for certain classes are missing. For
instance, some of them are not noted in procedures, while others are not noted in laboratories, and so on.
Missing values are replaced by 0 if they pertain to diagnosis, procedures, and medications
(because if a patient does not have a record indicating comorbidity, it means he was not
diagnosed with it (0)). Otherwise, if they belong to labs and vitals, they drop from the
data(when a patient doesn’t have a record, we can not replace it by 0, which is used for
tests with normal results).
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3. Patients with no records
In each cohort, there were some patients who had no record at all. As a result, they were
not taken into account by our analysts and dropped from the datasets.

3.8

Dividing cohorts by year

As previously noted, we identified three cohorts and followed patients within cohort 1 for
three years and cohorts 2 and 3 for five years before developing CKD. Then to make comparison between cohorts, we changed all cohorts to three years, and separated them yearly,
such as one, two, and three years before to CKD, to investigate if the clinical features altered
annually prior to CKD or not. The goal is to group patients within each cohort by passing
time in order to more clearly identify the phenotypes for each year.
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So far, we have generated patient groups in accordance with the study’s planned objective. The next step is to look at these cohorts to see if there are any patterns or similarities
between them or even within them. The objectives of this portion of the statistical analysis are to identify common tendencies and to convert them into meaningful, comprehensive
information. Data mining algorithms are statistical models that are typically used for analyze big data to increase the speed and accuracy of data processing. Before using machine
learning (ML) techniques, data mining methods are frequently used to investigate data and
build models to find important patterns, groupings, and trends between datasets. This makes
ML algorithm quicker and more accurate. We made the decision to use several data mining
approaches and select appropriate ML algorithms for each of them.

4.1

Clustering

Clustering is a data mining technique which divides the data into several distinct groups so
that data points in a group are more similar to each other compared to the data points in a
different group. On another words, within group variation is far less compared to the between
group variation. The groups are created based on different combinations of the underlying
variables. Clustering helps us to unwrap the hidden structure in the data, capture different
characteristics in separate clusters and summarize the data in a meaningful way. Clustering
is an unsupervised learning technique. Unlike classification, the clustering method has no
predefined classes. It needs less or no information for analyzing the data. There are several
clustering algorithms which can be used to analyze our data. In this research, we choose
to utilize two clustering algorithms from two different families, namely K-means clustering
which represents the traditional heuristic based approaches and latent class analysis (LCA)
which represents the statistical model based approaches. They both are discussed in this
section. However, to produce meaningful clusters and to interpret these clusters for decision
making we need additional methods to make the data ready for clustering and finding important variables from resulting clusters. These methods are known as Dimensionality reduction
and variable selection approach. They are discussed in more detail below.
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4.1.1

Dimensional reduction and variable selection

For cohort 1, there are 1322 variables, and for cohorts 2 and 3, there are 1910 variables. Cohort
1 has been divided into three years, while cohorts 2 and 3 have been divided into five years.
We have 782 variables for every year, including 50 diagnoses, 100 procedures, 132 lab results
and vital signs (33 for every three months over a year), and 500 medications. We looked at
patients on an annual basis to determine if their profiles changed over time.
The new cohorts still have an excessive number of variables. In order to assist ML algorithms learn and uncover significant patterns when dealing with big data, we first take into
account as many variables as we can. However, this slows down the learning process for ML
algorithms, increases overfitting, and makes the data difficult to interpret. Thus, dimensional
reduction of the data is required. It helps the algorithms to reduce the number of features
without losing much information and helps to improve the model.
Algorithms for dimensionality reduction are different. Based on the goal of the project
and the available dataset, the best algorithm can be chosen. However, there are two groups
into which different dimension reduction techniques can be divided:
1. Features selection: Techniques are employed to choose the most important variables
among existing known characteristics and features. In this instance, a technique called
random forest is applied.
2. Features extraction: The process of feature extraction comprises reducing the number of
features and linearly merging them. The dimensionality reduction has resulted in several
significant principle components, similar to those found using the PCA technique.
Both techniques for dimension reduction were applied in this study. Before using K-means,
logistic PCA was utilized for cohort analysis, and the random forest method was employed
to identify key factors for each cluster in LCA.

4.1.2

Logistic PCA

Principal component analysis (PCA) is the feature extraction method in data science that
helps keep the maximum amount of information by decreasing the number of features . PCA
removes correlated features and reduces over-fitting. Reducing the dimension means losing
the information. In PCA, the cumulative variance of the remaining data helps us to maintain
the desired accuracy.
PCA decreases the number of variables to P components, where each component is the
linear combination of the original variables in the way that keep maximum variation of the
original variables. Principal components are orthogonal at the points of their intersections.
In another word, the original data project to the p vectors and the best fit is one which
minimize the average squared distance of points to the p vectors. To project the data into a
new subspace with fewer dimensions, PCA technically seeks the eigenvectors of a covariance
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matrix with the greatest eigenvalues and uses those. Practically, PCA creates a new dataset
of less than n features from a matrix of n features. In other words, it decreases the number
of features by creating new, fewer variables that effectively capture a significant amount of
the data included in the original features.
The previous data files were replaced by the new data files, which is obtained through
logistic PCA. The number of patients is unchanged in the new data files; the number of variables changed to principal components, and the data value has changed to the logistic PCA
score[40, 41]. Figure 4.1 shows the steps of logistic PCA.

Figure 4.1: Logistic PCA steps

.

We have binary datasets, so we used logistic-PCA. It is a dimensionality reduction algorithm for binary data. For binary datasets like our dataset, the parameters project from the
Bernoulli concentration model and minimize the Bernoulli variance.[42].
Before performing the K-means clustering, we extracted features using the R package LogisticPCA. This package needs two hyperparameters to be defined. m is a tuning parameter
or principal component score, and k is the total number of principal components. Since the
saturated parameters that come from natural parameters have both positive and negative
values, tuning parameters are employed to regularize and approximate them. The m is utilized by cross validation to minimize over-fitting by choosing a number of random subsets of
the data and measuring their average error, so the best hyperparameter is the value with the
lowest cross validation value. On the other hand, k, which specifies the number of principal
components, would be chosen in accordance with the original dataset variation that was desired to be maintained. The variance of the original dataset increases with a higher number
of k. We decide to retain 80% of the variation from the original datasets in this section, and
we then determine the k (number of components) that best serves our objectives.

4.1.3

K-means clustering

K-means clustering is one of the widely used data clustering methods which attempts to
form k-centroids for k-clusters and assign data points to their nearest clusters based on their
distances to these centroids. Initially, it starts with some random locations as centroids and
then try to optimize their locations in an iterative fashion.This is not a model-based method
and doesn’t follow a statistical method. It is appropriate for large and complex data sets. It
is relatively quick and can join clusters when necessary. It produces comparatively accurate
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clustering if clusters are spherical and evenly sized. K-means algorithms can be applied using
following steps:
a) First, we choose K as an arbitrary number of the clusters to start.
b) Random K points are chosen as the center for each cluster.
c) Each data point are assigned to its nearest centroid, which will create the K clusters that
have been defined.
d) The k centroid elements are recomputed and modify their positions after all the objects in
the space have been assigned. Random K points are chosen as the center for each cluster.
e) Steps (c) and (d) are repeated until the centroids reach a position where they no longer
change with respect to the distances between all the elements of their group.
K-means clustering has one hyperparameter, so it must be manually defined. This hyperparameter is the number of clusters(K). Choosing a k is the initial stage in K-means clustering,
as indicated above. The best choice is better to made because, More clusters would explain
more variance, but fewer points would be contained in each cluster and cause decreasing
persistence. The initial clusters are designed to contribute a lot of information and are thus
required since there are actually that many groups in the data. However, as it is just partitioning the real groups, the additional information will rapidly decrease if the number of
clusters gets too large in the data.
Elbow Method
The best k value can be determined using a variety of techniques. The elbow technique is
one of these techniques that has been used in this research as it is easy to understand and
is based on the variance of the points in each cluster. The elbow method measures the value
of the within cluster sum of squares (wcss) for different numbers of clusters and plots them.
The best number of clusters is the point where the wcss doesn’t have sharp changes.
The k-means clustering method fitted k clusters based on the results of the elbow method,
and then patients were assigned to the clusters..Elbow method and K-means have been implemented by the Sklearn package in Python.

4.1.4

Latent class analysis (LCA)

Latent class analysis (LCA) is a finite mixture model based clustering approach. It uses a probability model to describe the underlying distribution of the data and generates two or more
subgroups of latent classes. Different from K-means algorithm, LCA develops latent classes
and decide clustering membership based on these classes instead of the original variables.
For each data point, LCA returns a probability of class assignment (soft assignment) instead
of a hard assignment. It is considered to be more advantages than traditional clustering, as it
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uses statistical methods for assigning points to clusters and can find the optimal number of
clusters by following specific criteria. In LCA, we can statistically test each of the alternative
models and choose a statistically significant model. Being backed up by statistical theories,
LCA is more preferred in analyzing health care data. However, LCA is computationally much
slower than the K-means clustering.
LCA classifies individuals based on their maximum likelihood within each class. Imagine
each class is a disease and the patients belong to each class based on their disease. As a result,
when a patient has multiple diseases, his symptoms are related. The purpose of LCA is to
develop latent classes within which there is no longer any association between one symptom
and another, so the symptoms will be conditionally independent because the class is the
disease that causes their association. One important feature of latent classes is that their
variables are independent of one another, and the relationship between variables is defined
by the latent variable classes.
LCA provides us with more interpretable clustering because it is a probability distributionbased clustering and make more sense medically. It also shows us the prevalence of variables
in each cluster. The prevalence is the proportion of patients who have specific variables in
clusters. It helps us find the presence of a variable in each cluster and, generally, the change
in its attendance in different clusters. These are also the reasons we used LCA clustering.
PoLCA, a R package for LCA, was used to implement LCA. Based on the Bayesian information criterion (BIC) and degree of freedom, we decided how many clusters to create.
By minimizing the Bayesian information loss function, BIC estimates the accuracy of the fit.
In this case, a smaller BIC is preferable. Higher degrees of freedom are required for more
clusters, and the quantity of variables has an impact on this. PoLCA is applicable to positive integers, so we apply it to the original binary dataset by changing the value of zero to
another integer. And we didn’t use logistic PCA before applying LCA because the principal
component scores were not positive integers.
LCA had applied for three cohorts, year by year over three years. LCA was applied to a couple of clusters (k = 4 through 8).Based on the degree of freedom, the number of clusters was
constrained. We required extra variables to support more clusters. So, out of k = 4, 5, 6, 7, and
8, we decided on k = 5 for each of the three cohorts’ three years based on the lowest value for
The Bayesian information criterion (BIC).The BIC, is the standard by which a model is judged
against a limited set of other models. For the majority of the cohort years, we established
the BIC minimum value for k = 5, however according to a little variance in value, the best BIC
was for more clusters in some of the cohorts. As a result, we ultimately opted to apply LCA
for k = 5 for all years in all cohorts due to the little variance.

4.1.5

Random forest

To find the differences and similarities between LCA’s clusters and name them after LCA
has been implemented, we need to identify the most crucial variables in each cluster. In
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order to accomplish this, we used feature selection. There are several advantages to feature
selection: first, it makes the model easier to interpret; second, ML models work faster with
fewer features; third, it will improve the accuracy of the model and decrease over-fitting.
One of the most popular ML methods for variable selection is random forest. The weight
of each feature in a random forest is determined using gini importance or the mean decrease
average (MDA). This is the reduction in likelihood ratio or accuracy caused by the removal
of a variable. The significance of the variable increases with the size of the decline. Here, the
mean decline plays a key role in determining which variables to use.This method is one of
the subsets of embedded methods, and its benefit is that it decreases over-fitting. It is also
easy to interpret. So, we apply this method to find our most important variables.
The random forest algorithm can be applied by the following steps:
i. First, from the given data set, random samples(e.g., 1000) are selected.
ii. Then this algorithm will construct a decision tree for every sample. and it will get the
prediction result from every decision tree.
iii. Taking into account how many times each prediction is reported
iv. The most reported prediction is chosen as the final prediction.
In this research, we used the random forest package in R to find the most important
variables in each cluster based on the MDA for each variable. Then we used Jaccard similarity
index to find the similarity and difference of clusters in each cohort during different years.
For example similarities between clusters in year 1 cohort 1 vs. year 2 cohort 1 vs. year 3
cohort 1 and so on.

4.2

Outcome measures

Three outcomes are measured by this study:
1. Comparison of Clustering Methods
The matching of patients for class assignment using two clustering methods was investigated in order to determine how patients were assigned using K-means clustering and
LCA. It was used to validate LCA as a statistical method.
2. Important Variables
Important variables were discovered in order to find phenotypes in each cluster, year, and
cohort in general.
3. Prevalence Calculation
The prevalence of a certain attribute in a population is measured in each cluster, year, and
cohorts in general.
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4.3

Similarity measures

The Jaccard similarity index was used to measure similarity of patients clustering across years
before CKD. We want to see how patients change their clusters by time.
The Jaccard similarity index determines the similarity between two sets of data. The
range of the Jaccard similarity index is 0 to 1. If it is 1, it means that two datasets are fully
comparable, and if it is 0, it means that the datasets are fully dissimilar. Jaccard similarity
index divides the number of comparable data in two datasets by the total number of data in
the two datasets.
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This chapter considers the results of clustering and data mining methods for the three
study cohorts. In the case of comparisons, three years prior to CKD were considered and
analyzed cohort by cohort and year by year. Patient profiles in general had been compared
between three study cohorts, and for more details, cohorts were considered year by year.

5.1

Patient population

A total of 75033 CKD patients were studied, with 21547 (28.72%) having AKI prior to CKD,
13351 (17.79%) having AKI after CKD, and 39280 (52.35%) having never had AKI. Patients
with AKI prior to CKD and those who had never experienced AKI created three study cohorts. Cohort 1 contains 7442 patients, or about 10% of all CKD patients; cohort 2 contains
6408 patients, or 8.5% of all CKD patients; and cohort 3 contains 39280 patients, or 52% of all
CKD patients. Other CKD patients were left out of this study. Demographics, ethnicity, and
comorbidities were compared for three study cohorts in table 5.1.
Patients in cohort 1 who were hospitalized 90 days before AKI had a significantly lower
age (69.35 (62-79)), a significantly higher BMI(30.93(25.79 - 35.49)), a higher proportion of
male (3820 (48.64%)) and white patients (6462 (86.83%)), a higher prevalence of comorbidities such as hypertensive diseases (92%), disorders of lipoprotein metabolism and other lipidemias (78.34%), type 2 diabetes mellitus (59.42%), Other long term (current) drug therapy
(86.09%), disease of the blood and blood-forming organs (68.07%), long-term (current) aspirin
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use (61.25%), atrial fibrillation and flutter (42.71%), atherosclerotic heart disease of the native coronary artery without angina pectoris (59.27%), unspecified chest pain (50.75%), and
chronic obstructive pulmonary disease (43.36%) in contrast to patients in cohort 3.
Additionaly, patients in cohort 2 compared to patients in cohort 3, for same variables as
cohorts 1 and 3. Patients in cohort 2 who had not hospitalized before AKI, had a significantly
lower age (69.55(62 - 79)), a significantly higher BMI(30.97(25.86 - 35.49)), a higher proportion
of male (3165 (49.39)) and white patients (5701(88.97)), a higher prevalence of comorbidities
such as hypertensive diseases (94.4%), disorders of lipoprotein metabolism and other lipidemias (83.44%), type 2 diabetes mellitus (62.97%), Other long term (current) drug therapy
(91.46%), disease of the blood and blood-forming organs (72.88%), long-term (current) aspirin
use (67.21%), atrial fibrillation and flutter (45.88%), atherosclerotic heart disease of the native coronary artery without angina pectoris (64.42%), unspecified chest pain (58.61%), and
chronic obstructive pulmonary disease (58.31%) in contrast to patients in cohort 3 (Table 5.1).
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Cohort 3

P-value

Cohort 2

Cohort 3

P-value

67(0.17)
1260(3.21)
23(0.06)
32410(82.51)
5520(14.05)
31182(79.38)
27929(71.1)
17085(43.5)
24715(62.92)
14645(37.29)
14974(38.12)
8822(22.46)
14310(36.43)
9466(24.090
9212(23.45)

10(0.13)
283(3.80)
3(0.04)
6462(86.83)
684(0.19)
6847(92.00)
5830(78.34)
4422(59.42)
6407(86.09)
5066(68.07)
4558(61.25)
3179(42.71)
4411(59.27)
3777(50.75)
3227(43.36)

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

0.4809
0.0109
0.5408
0.006
<0.0001
6050(94.4)
5347(83.44)
4035(62.97)
5861(91.46)
4670(72.88)
4307(67.21)
2940(45.88)
4128(64.42)
3756(58.61)
3096(48.31)

7(0.11)
240(3.75)
3(0.05)
5701(88.97)
457(7.13)

31182(79.38)
27929(71.1)
17085(43.5)
24715(62.92)
14645(37.29)
14974(38.12)
8822(22.46)
14310(36.43)
9466(24.090
9212(23.45)

67(0.17)
1260(3.21)
23(0.06)
32410(82.51)
5520(14.05)

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0
<0.0001

0.2582
0.0305
0.7150
<0.0001
<0.0001

69.35(62 - 79)
71.07(65 - 80)
<0.0001 69.55(62 - 79)
71.07(65 - 80)
<0.0001
30.93(25.79 - 35.49)
30.62(25.9 - 34.67)
0.0003
30.97(25.86 - 35.49)
30.62(25.9 - 34.67)
0.0001
3820(48.64)/3620(51.33) 18317(46.63) /20951(53.34) <0.0001 3165 (49.39)/3241(50.58) 18317(46.63) /20951(53.34) 0.0144

Cohort 1

Table 5.1: Clinical characteristic in all cohorts

Demographics
Age(years)(IQR)
BMI(kg/m2)(IQR)
Gender(M/F)%
Ethnicity
Asian(%)
Black or African American(%)
Native Hawaiian or Other Pacific Islander(%)
White(%)
Unknown(%)
Comorbidities
Hypertensive diseases(%)
Disorders of lipoprotein metabolism and other lipidemias(%)
Type 2 diabetes mellitus(%)
Other long term (current) drug therapy(%)
Disease of the blood and blood forming organs(%)
Long term (current) use of aspirin(%)
Atrial fibrillation and flutter(%)
Atherosclerotic heart disease of native coronary artery without angina pectoris(%)
Chest pain, unspecified(%)
Chronic obstructive pulmonary disease(%)
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5.2

Logistic PCA and K-means clustering results

The logistic PCA was applied to the original data set before applying the K-means clustering.
K-means clustering is a centroid-based method, so it works better for smaller dimensions of
the dataset. Logistic PCA reduces the dimension of the data by reducing the number of variables. The associated cumulative explained variance derived from logistic PCA for varying
numbers of principle components between 1 and the total number of variables in each year
of cohorts (774), had been kept to retain 80% of the variance of the original data. As a result
the number of variables is reduced to the principal components as shown in Table 5.2.
Figure 5.1 shows the change in cumulative explained variance for different numbers of principal components for cohort 1. If all of the original variables were retained, the cumulative
explained variance would be equal to one, as expected. Figures for cohorts 2 and 3 are available in the appendix A.
Cohort 1

P

Cohort 2

P

Cohort 3

P

Year 1

33

Year 1

55

Year 1

5

Year 2

23

Year 2

39

Year 2

2

Year 3

20

Year 3

30

Year 3

2

Table 5.2: Principal Components

After that we applied K-means clustering to analyze the results of the logistic PCA. The
best number of clusters for K-means has been determined using the elbow method. The
elbow method was designed to see how the variance was distorted or changed by varying
the number of clusters between 1 and 9. The optimum number of clusters is the number
of clusters after which the distortion of variance is minimized by increasing the number of
clusters after it. It also depends on how it is interpreted.
Figure 5.2 show the results of elbow method for the year 1 cohort 1, year 2 cohort 1, and
year 3 cohort 1. Similar work was done for year 1 cohort 2, year 2 cohort 2, year 3 cohort 2,
year 1 cohort 3, year 2 cohort 3, and year 3 cohort 3. Figures for cohorts 2 and 3 are available
in the appendix B. Table 5.3 shows the number of clusters selected by the elbow method for
each year in each cohort.
Cohort 1

K

Cohort 2

K

Cohort 3

K

Year 1

4

Year 1

4

Year 1

6

Year 2

4

Year 2

5

Year 2

4

Year 3

4

Year 3

4

Year 3

4

Table 5.3: Number of clusters selected for K-means clustering by the elbow method
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(a)

(b)

(c)

Figure 5.1: The number of principal components for cohort 1. (a) year 1; (b) year 2; (c) year 3 .
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(a)

(b)

(c)

Figure 5.2: The Elbow Method showing the optimal number of clusters (k). (a) year 1; (b) year 2; (c)
year 3 .
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The next step after finding the optimum number of clusters is fitting K-means clustering
to the data set for a number of clusters calculated by the elbow method. For example, years
1, 2, and 3 for cohort 1 are fitted to K-means for k = 4, year 1 cohort 2 is fitted to k = 4,
year 2 cohort 2 is fitted to k = 5, and so on. Clusters of K-means are shown in figure 5.3 to
help visualize and better understand the K-means clustering. These plots belong to the year
1 cohort 1, the year 2 cohort 1, and the year 3 cohort 1. Similar work was done for year 1
cohort 2, year 2 cohort 2, year 3 cohort 2, year 1 cohort 3, year 2 cohort 3, and year 3 cohort
3. Figures for cohorts 2 and 3 are available in the appendix C.
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(a)

(b)

(c)

Figure 5.3: Clusters of K-means for cohort 1. (a) year 1; (b) year 2; (c) year 3.

To visualize K-means clustering, data points are projected on two axes; the values on the x
and y axes are connected to these two PCs and do not exhibit a distinctive variable.
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5.3

Latent class analysis (LCA) and variable selection results

LCA is only applicable to positive integer data, so we couldn’t use it on the logistic PCA files
because the PCA scores aren’t positive integers. Instead, we used LCA on the original dataset
with the original variables. After LCA, each patient was assigned a cluster between 1 and 5,
and then a random forest was applied to the data. For each cluster in each year, we found
the top 10 most important variables based on the mean MDA value that random forest gave
us, from each group of variables (diagnosis, procedures, medications, lab results, and vitals).
Additionally, we discovered each year’s prevalence probability for every cluster. The rate of
patients who have particular variables in each cluster is shown by the prevalence probability.
For instance, if the variable is hypertension and it equals 0.9 for cluster 1, 90% of the patients
in cluster 1 have hypertension, and so on.
We could not label the clusters using the important clustering factors because we couldn’t
find any transparent instructions or information. There were too many common variables
in clusters. Instead, we used the similarity and dissimilarity of important variables across
clusters to find out the important variables across years and cohorts.
This study demonstrates that the risk varies depending on the patient group, and clustering helps highlight the significance. From the prevalence probability tables for each year,
we choose five variables as an example to demonstrate this. All of these variables had a high
prevalence probability in one or more clusters while having a low prevalence probability in
others. Figure 5.4 illustrates it for three years in cohort 1, Figure 5.5 illustrates it for three
years in cohort 2, and Figure 5.6 illustrates it for three years cohort 3. Two factor levels (Pr(1)
denotes the proportion of variables’ existence on a cluster, while pr(2) denotes its absence) are
represented in these graphs by the colors orange and blue. and they illustrate the likelihood
that a certain cluster will include a particular variable.
For instance, sodium chloride, which is one of the important factors in year 1 cohort 1, is
an important phenotype for patients in classes 1, 4, and 5, with a probability of more than
80%; however, for patients in classes 2 and 3, it is a phenotype without any statistical test.
On the other hand, hypertensive disease, three years prior to CKD for patients in cohort
1, classes two, three, and four, is an important phenotype, as almost all patients in these
classes are diagnosed with it, but in classes one and five, it doesn’t seem to be a phenotype.
Ondansetron hydrochloride is a drug that has been identified as an important phenotype for
most of the classes in cohort one during all three years. Two to three years before diagnosis,
hypertensive diseases are significant phenotypes for CKD. For Cohort 2, the prothrombin
time test and the partial thromboplastin time test are both phenotype for some patients
during the first year prior to CKD. Two years prior to CKD, breathing abnormalities are one
of the most important phenotype for some groups of patients. Three years prior to CKDrelated hypertension disease, as in cohort 1, are important phenotype.
For cohort 3, cough was found as a prevent phenotype for year 1. Again, sodium chloride
is a phenotype for year 1 in cohort 3 for specific groups of patients, same like year 1 in cohort
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1. Collection of venous blood is a phenotype for some groups of patients two years prior to
CKD in ”all three cohorts.” Fentalycitrate is a phenotype in year 2 for cohorts 2 and 3, but
not for cohort 1. Hypertensive disease is a phenotype three years prior to CKD for all three
cohorts.
Here are a few examples of how clustering can be used to identify phenotypes over time for
various patient groups across various study cohorts.
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(a)

(b)

(c)

Figure 5.4: Variable prevalence in different clusters based on the LCA method for cohort 1. (a) year
1; (b) year 2; (c) year 3 .

Pr(1) denotes the proportion of variables’ existence on a cluster, while pr(2) denotes its absence.
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(a)

(b)

(c)

Figure 5.5: Variable prevalence in different clusters based on the LCA method for cohort 2. (a) year
1; (b) year 2; (c) year 3 .

Pr(1) denotes the proportion of variables’ existence on a cluster, while pr(2) denotes its absence.
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(a)

(b)

(c)

Figure 5.6: Variable prevalence in different clusters based on the LCA method for cohort 3. (a) year
1; (b) year 2; (c) year 3 .

Pr(1) denotes the proportion of variables’ existence on a cluster, while pr(2) denotes its absence.
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In order to determine whether or not demographic factors may be taken into account as
phenotypes, we also took into account the age, sex, and race of patients in each class. As
a result, as shown in Table 5.1, none of age, gender, or race can be considered phenotypes
for the various cohort 1 groups because they are all close; the average age for patients in all
clusters is close to 70 years old, and almost 90% of patients were white. The demographic data
for cohorts 2 and 3 are shown in tables 5.2 and 5.3. Tables indicate that in Cohort 2 year 1, in
the first cluster, the majority of people were female (66.67%). A partial thromboplastin time
test is a phenotype in this group of patients. Additionally, the majority of patients in cohort 2
year 3 were female (66.67%) . Sodium chloride and venous blood collection and hypertensive
disease are not phenotypes for this cluster, however, radiologic evaluation of the chest is.
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Race

Age

Sex

Race

Age

Sex

Race

Age

Sex

C1
53.83
46.12
69.3(12.9)
0.23
2.97
0
86.31
10.49

C1
53.83
46.12
69.3(12.9)
0.23
2.97
0
86.31
10.49

C1
50.55
49.43
72.8(12.5)
0.16
3.62
0.1
82.92
13.21

Male
Female
mean(SD)
Asian
Black or African American
Native Hawaiian or Other Pacific Islander
White
Unknown

Male
Female
mean(SD)
Asian
Black or African American
Native Hawaiian or Other Pacific Islander
White
Unknown

Male
Female
mean(SD)
Asian
Black or African American
Native Hawaiian or Other Pacific Islander
White
Unknown

Year 1
C3
49.26
50.68
67.22(12.4)
0.25
2.4
0
91.88
5.47
C4
58.62
41.38
67.5(15.6)
0
0
0
82.76
17.24

C5
51.27
48.73
70.97(12.6)
0.05
3.77
0.05
88.53
7.6

C1
52.52
47.48
70.16(13.13)
0.27
3.01
0
87.07
9.65

C2
50.41
49.59
70.12(12.1)
0.14
2.88
0
92.33
4.66

Year 2
C3
51.37
48.57
69.28(12.6)
0.13
3
0
88.53
8.35
C4
52.03
47.97
70.5(12.4)
0.11
4.17
0.11
91.33
4.28

C5
45.33
54.67
67.2(12.7)
0.11
2
0
93.67
4.22

Year 1
C3
49.26
50.68
67.22(12.4)
0.25
2.4
0
91.88
5.47
C4
58.62
41.38
67.5(15.6)
0
0
0
82.76
17.24

C5
51.27
48.73
70.97(12.6)
0.05
3.77
0.05
88.53
7.6

C1
52.52
47.48
70.16(13.13)
0.27
3.01
0
87.07
9.65

C2
50.41
49.59
70.12(12.1)
0.14
2.88
0
92.33
4.66

Year 2
C3
51.37
48.57
69.28(12.6)
0.13
3
0
88.53
8.35
C4
52.03
47.97
70.5(12.4)
0.11
4.17
0.11
91.33
4.28

C5
45.33
54.67
67.2(12.7)
0.11
2
0
93.67
4.22

Year 1
C3
42.15
57.85
69.8(12.5)
0.17
3.1
0.05
91.48
5.19
C4
48.67
51.28
71.4(12.8)
0.14
2.84
0.06
77.83
19.13

C5
41.58
58.39
71.3(12.3)
0.06
1.95
0
92.34
5.65

C1
38.66
61.34
71.28(12.1)
0
2.02
0
94.77
3.21

C2
49.79
50.21
70.8(12.9)
0.08
3.26
0.06
84.78
11.76

Year 2
C3
43.64
56.34
72.05(11.8)
0.23
2.64
0.02
92.09
5.02

C4
40.37
59.63
70.3(12.6)
0.16
2.64
0.03
93.64
3.54

C5
47.85
52.11
71.3(12.9)
0.2
2.9
0.09
80.4
16.41

Table 5.6: Demographic information based on the clusters for cohort 3

C2
46.18
53.81
70.7(12.7)
0.24
2.69
0.04
85.31
11.72

Table 5.5: Demographic information based on the clusters for cohort 2

C2
0
100
20(0)
0
0
0
100
0

Table 5.4: Demographic information based on the clusters for cohort 1

C2
0
100
20(0)
0
0
0
100
0

C1
38.61
61.39
70.53(12.7)
0.03
2.3
0
94.9
2.77

C1
49.2
50.8
70.1(12.2)
0
3.02
0
92.9
4.09

C1
49.2
50.8
70.1(12.2)
0
3.02
0
92.9
4.09

C2
46.96
53
71.41(12.6)
0.23
3.19
0
84.53
12.04

C2
49.14
50.79
68.81(12.8)
0.15
2.7
0.08
87.23
9.84

C2
49.14
50.79
68.81(12.8)
0.15
2.7
0.08
87.23
9.84

Year 3
C3
42.82
57.18
71.9(11.9)
0.26
3.23
0.03
93.33
3.15

Year 3
C3
53.42
46.58
69.4(12.6)
0
3.74
0
92.71
3.56

Year 3
C3
53.42
46.58
69.4(12.6)
0
3.74
0
92.71
3.56

C4
46.83
53.17
70.28(12.9)
0.11
2.22
0.05
88.53
9.09

C4
54.08
45.92
70.8 (13.3)
0.34
3.35
0
88.33
7.98

C4
54.08
45.92
70.8 (13.3)
0.34
3.35
0
88.33
7.98

C5
48.15
51.82
71.32(12.7)
0.15
2.92
0.1
81.56
15.26

C5
45.3
54.7
68.3(12.3)
0.24
2.56
0
92.92
4.27

C5
45.3
54.7
68.3(12.3)
0.24
2.56
0
92.92
4.27
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5.4

Comparison of LCA clusters with K-Means clusters

For years 1, 2, and 3 in cohort 1, the elbow generating an ideal k of 4, while LCA produced an
ideal number of clusters of 5. Based on the LCA and K-means, we attempted to determine how
closely a patient’s class fits, and we compared these two approaches to see if they produced
comparable or dissimilar findings. So, we discovered patients who were assigned to cluster 1
using K-means and then see how they were assigned using LCA. Figure 5.7 compares K-means
clustering and LCA for year 1 in cohort 1.
For year 1, as shown in figure 5.7, almost all patients in the first k-means cluster were in
the third LCA cluster. The first LCA cluster contained about 75% of the patients in the second
k-means cluster and 60% of the patients in the fourth k-means cluster. Eighty percent of the
patients in the fifth LCA cluster are in the third K-means cluster. Patients allocated to classes
2 and 4 by LCA did not share classes when using the k-means clustering approach. It could
be because there are more classes in LCA than in k-means. Moreover because LCA is a more
trustworthy clustering technique than k-means, which is a centroid technique.

(a)

(b)

(c)

(d)

Figure 5.7: Comparison of K-means clustering with latent class analysis (LCA) in year 1 cohort 1
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Patients in the first cluster were assigned by k-means 40% to cluster 2, and 50% to cluster
4 by LCA in year 2 of cohort 1. Likewise, 90% of patients in the second k-means cluster were
assigned to the third LCA cluster. The first LCA cluster was assigned to 60% of patients in
the third k-means cluster, and the fifth LCA cluster was assigned to nearly 90% of patients in
the fourth k-means cluster.
Therefore, for year 2 cohort 1, the first k-means cluster corresponds to the second and
fifth LCA cluster, the second k-means cluster corresponds to the fourth LCA cluster, the
third k-means cluster corresponds to the first LCA cluster, and the fourth k-means cluster
corresponds to the fourth LCA cluster. As a result, in year 2 of Cohort 1, k-means closely
satisfy LCA clustering on patient profiles.

(a)

(b)

(c)

(d)

Figure 5.8: Comparison of K-means clustering with latent class analysis (LCA) in year 2 cohort 1
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For cohort 1’s year 3 patients, 65% of those in the first k-means cluster are matched with
the second LCA cluster, 65% of those in the second k-means cluster are matched with the
fourth LCA cluster, 55% of those in the third k-means cluster are matched with the first LCA
cluster, and nearly all of those in the fourth k-means cluster are matched with the fifth LCA
cluster. The clustering of patient profiles by LCA will be satisfied if, as in year 2, we are able
to identify a corresponding cluster for each of the k-means classes in the LCA.
Because the LCA is a more credible technique than K-means, we chose its outcomes for our
investigation. Additionally, we made comparable comparisons of years in Cohorts 2 and 3
using k-means and LCA. The appendix D contains the figures for similarity comparisons.

(a)

(b)

(c)

(d)

Figure 5.9: Comparison of K-means clustering with latent class analysis (LCA) in year 3 cohort 1
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5.5

Cohort comparison and insights

In this part, we used the Jaccard similarity index to see if patients changed their cluster over
the years. For instance, patients in class 1 year 1 move to class 1 year 2, or class 2 year 2,
or class 3 year 2, and so on. We were attempting to determine whether or not there was a
pattern for patients moving across years. During all three cohorts, we calculated the Jaccard
similarity index between clusters for years 1 vs. 2, years 1 vs. 3, and years 2 vs. 3. Figure 5.10
shows the results for cohort 1. Jaccard similarity figures for cohorts 2 and 3 are available in
the appendix E.
Jaccard’s similarity index in general changes between 0 and 1. Index 0 indicates that there
is no similarity, while index 1 indicates that they are completely similar. Low levels of patient
similarity are evident in clusters, as seen in Figure 5.10. The greatest similarity index between
the first and second years is 0.35; between the first and third years is 0.29; and between the
second and third years is 0.46. The approach to indicate the Jaccard similarity index value and
pair the colors with numbers can be seen in the line on the right of figure 5.10. This indicates
that most patients’ clusters change over time. Jaccard similarity, thus, failed to provide us
with a clear direction across clusters in years; as a result, we decided to consider cohorts year
by year.
In the rest of this research, we considered the similarities and dissimilarities among cohorts
across years. For example, cohort 1 year 1 vs. cohort 2 year 1 vs. cohort 3 year 1. Then we
repeated the process for the following years. for diagnosis, procedure, medication, vitals, and
labs. Also, we considered similarities and dissimilarities between Cohort 1 vs. Cohort 2 vs.
Cohort 3.
As previously stated, we used random forest to determine the top ten significant variables
for each cluster based on the MDA. It is important to take into account all categories of
factors, such as diagnosis, procedures, medication, lab results, and vital signs. There were
too many variables that were shared between clusters. We then eliminated similar factors
from the data and maintained just the most significant ones for each year in each cohort
in order to compare and contrast patients in each year. Then, in order to compare them
and discover similarities and differences between cohorts in the same year prior to CKD,
we gathered all variables for several cohorts in the same year at one table. Similarly, we
gathered the significant variables in each cohort to compare three cohorts. During the three
years, important variables for each cohort were gathered and compared with those of the
other cohorts.
Along with the comparison of cohorts overall, each set of factors had its own considerations for the comparison of cohorts in each year and generally over three years. Details
regarding the diagnosis, procedures, medications, lab results, and vital signs can be found
below. All tables in this chapter are sorted based on the importance score (MDA) of variables.
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(a)

(b)

(c)

Figure 5.10: Jaccard similarity index for cohort 1.
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5.5.1

Diagnosis

Important phenotypes during the year prior to CKD for all three cohorts are gathered on table
5.4. We can find ”abnormal electrocardiogram [ECG] [EKG],” ”abnormalities of breathing,”
and ”cardiomegaly.” ”Chronic ischemic heart disease,” ”heart failure,” ”hypertensive diseases,”
”major depressive disorder, single episode, unspecified,” ”other long-term (current) drug therapy,” ”other specified postprocedural states,” and ”pleural effusion” are common phenotypes
in all three cohorts during year 1, so we can say that they can be phenotypes one year prior
to CKD because this is a common criteria in all three cohorts.
In cohorts 1 and 2, common phenotypes include ”anxiety disorders,” ”hypokalemia,” ”localized edema,” and ”other chronic pain.” These factors are not in cohort 3, which was one
year prior to CKD, so as the patients in cohorts 1 and 2 had prior AKI, we can say that these
factors can be an outcome of AKI, which can increase the risk of CKD.
We have some factors that were present in cohort 1 during year 1 but were not in cohorts 2 or 3, such as ’Dorsalgia, unspecified’, ’Long term (current) use of aspirin’, ’Diarrhea,
unspecified’, ’Long term (current) use of anticoagulants’, ’Constipation, unspecified’, ’Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm’, ’Unspecified abdominal pain’, ’Atrial.fibrillation.and.flutter’, ’Chest pain,
unspecified’, ’Atherosclerotic heart disease of native coronary artery without angina pectoris’,
’Urinary tract infection, site not specified’, ’Encounter for other preprocedural examination’,
’Overweight.and.obesity’, ’Hyperkalemia’, ’Nonrheumatic mitral (valve) insufficiency’. These
elements can be referred to as phenotypes for individuals who were hospitalized or had an
inpatient visit 90 days prior to AKI.
On the other hand, there are some variables uniquely for cohort 3 during year 1 such as
’Encounter for general adult medical examination without abnormal findings’, ’Encounter
for immunization’, ’Encounter for screening mammogram for malignant neoplasm of breast’,
’Encounter for screening for malignant neoplasm of colon’, ’Encounter for other preprocedural examination’, ’Long term (current) use of anticoagulants’, ’Chest pain, unspecified’,
’Atrial.fibrillation.and.flutter’, ’Nonrheumatic mitral (valve) insufficiency’, ’Long term (current) use of aspirin’, ’Unspecified abdominal pain’, ’Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm’. Because patients in
cohort 3 never had AKI, these characteristics can be referred to as CKD phenotypes that are
unrelated to AKI.
Similar conclusions may be drawn for the two and three years prior to the onset of CKD for
all cohorts based on the data available in similar tables in the appendix F.
To compare the cohorts in general, we gathered the most important variables of each cohort
over the course of three years in Table 5.5, regardless of yearly changes in patient profile.
As this table shows, we can conjecture that some phenotypes that are common between
cohorts 1 and 2, such as ”hypokalemia,” ”major depressive disorder, single episode, unspecified,” and ”other specified postprocedural states,” can be named as phenotypes of CKD for
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patients who had experienced AKI. Additionally, the three cohorts shared substantial characteristics that might be referred to as phenotypes for CKD, including ”abnormal electrocardiogram [ECG] [EKG], abnormalities of breathing, hypertensive diseases, and other longterm (current) pharmaceutical therapy.”. Furthermore, ”long-term (current) use of aspirin,”
”unspecified diarrhea,” ”chronic ischemic heart disease,” ”cardiomegaly,” ”unspecified chest
pain,” ”atherosclerotic heart disease of the native coronary artery without angina pectoris,”
”encounter for other pre-procedural examination,” and ”overweight and obesity” as unique
factors in cohort 1 can be considered phenotypes for CKD for patients who were hospitalized
or had an inpatient visit. And finally, ”encounter for general adult medical examination without abnormal findings,” ”encounter for immunization,” ”encounter for screening mammogram
for malignant neoplasm of the breast,” ”encounter for screening for malignant neoplasm of
the colon,” ”encounter for other preprocedural examination,” ”Vitamin D deficiency, unspecified,” and ”Long term (current) use of anticoagulants” as unique factors in cohort 3 can be
identified as phenotypes for CKD for patients who have never experienced AKI.
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Cohort1

Cohort2
Other long term (current)
drug therapy
Other specified
postprocedural states

Dorsalgia, unspecified
Long term (current) use of aspirin
Major depressive disorder, single episode, unspecified

Other chronic pain

Other long term (current) drug therapy

Hypertensive diseases

Other specified postprocedural states

Abnormal electrocardiogram
[ECG] [EKG]

Diarrhea, unspecified

Abnormalities of breathing

Chronic ischemic heart disease

Anxiety.disorders
Major depressive disorder,
single episode, unspecified
Chronic ischemic heart disease

Long term (current) use of anticoagulants
Constipation, unspecified
Encounter for follow-up examination after
completed treatment for conditions other
than malignant neoplasm
Abnormalities of breathing
Abnormal electrocardiogram
[ECG] [EKG]
Hypokalemia
Unspecified abdominal pain

Encounter for screening mammogram
for malignant neoplasm of breast
Encounter for screening for malignant
neoplasm of colon
Encounter for other preprocedural
examination
Abnormal electrocardiogram
[ECG] [EKG]
Hypertensive diseases
Vitamin D deficiency, unspecified
Other long term (current) drug therapy
Low back pain

Localized edema

Long term (current) use of
anticoagulants

Pleural.effusion

Chest pain, unspecified

Low back pain
Disorders of lipoprotein metabolism
and other lipidemias

Atrial fibrillation and flutter

Other fatigue

Anxiety disorders
Hypertensive diseases

Pleural effusion

Vitamin D deficiency, unspecified
Edema, unspecified
Disease of the blood and
blood forming organs
Heart failure

Atrial fibrillation and flutter

Hypokalemia

Chest pain, unspecified
Atherosclerotic heart disease
of native coronary artery without
angina pectoris
Urinary tract infection,
site not specified
Encounter for other
preprocedural examination
Overweight and obesity
Hyperkalemia
Localized edema
Heart.failure
Nonrheumatic mitral (valve) insufficiency

Encounter for immunization

Cardiomegaly

Cardiomegaly

Other chronic pain

Cohort3
Encounter for general adult medical
examination without abnormal findings

Heart.failure
Other specified
postprocedural states
Chronic ischemic heart disease
Abnormalities of breathing
Cardiomegaly
Pleural effusion
Disorders of lipoprotein metabolism
and other lipidemias
Nonrheumatic mitral (valve) insufficiency
Long term (current) use of aspirin
Major depressive disorder,
single episode, unspecified
Unspecified abdominal pain
Encounter for follow-up examination
after completed treatment for
conditions other than malignant neoplasm

Table 5.7: Year 1 diagnosis comparison
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Cohort1

Cohort2

Long term (current) use of aspirin

Other long term (current) drug therapy

Major depressive disorder,
single episode, unspecified

Other specified postprocedural states

Other long term (current) drug therapy

Hypertensive diseases

Other specified postprocedural states

Abnormal electrocardiogram
[ECG] [EKG]

Diarrhea, unspecified

Abnormalities of breathing

Chronic ischemic heart disease
Abnormalities of breathing
Abnormal electrocardiogram
[ECG] [EKG]
Hypokalemia
Cardiomegaly
Hypertensive diseases
Chest pain, unspecified
Atherosclerotic heart disease
of native coronary artery
without angina pectoris
Encounter for other
preprocedural examination
Overweight and obesity

Major depressive disorder,
single episode, unspecified
Pleural effusion
Disorders of lipoprotein metabolism
and other lipidemias
Disease of the blood
and blood forming organs
Hypokalemia

Cohort3
Encounter for general adult
medical examination
without abnormal findings
Encounter for immunization
Encounter for screening mammogram
for malignant neoplasm of breast
Encounter for screening for
malignant neoplasm of colon
Encounter for other
preprocedural examination
Abnormal electrocardiogram
[ECG] [EKG]
Hypertensive diseases
Vitamin D deficiency, unspecified
Other long term (current)
drug therapy
Long term (current)
use of anticoagulants
Abnormalities of breathing
Disorders of lipoprotein
metabolism and other
lipidemias

Table 5.8: Cohort comparison for diagnosis
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5.5.2

Procedures

This section discusses the procedure’s phenotypes over three years and three study cohorts,
as well as the consideration given for the diagnosis. The important variables for procedures
during the first year, second year, and third year prior to CKD for the three study cohorts are
considered. Table 5.6 shows these variables one year prior to CKD.
One year prior to CKD, there are several common variables in cohorts 1 and 2 of patients
who experienced AKI before CKD. These variables are ”blood CO2 analysis,” ”ABO blood
typing,” ”calcium ionized measurement,” ”potassium in plasma measurement,” ”therapeutic
procedure, one or more areas, each lasting 15 minutes,” and ”therapeutic exercises to develop
strength and endurance, range of motion, and flexibility”. Once more, all three cohorts share
some factors, such as ’Automated complete blood cell count (CBC) with automated differential leukocyte (WBC) count’, ’Long description: Prednisone, oral, per 5 mg Short description:
Prednisone oral’, ’Measurement of inorganic phosphorus (phosphate)’, ’Measurement of lactate (lactic acid)’ ’Prothrombin time test’.
For Cohort 1, one year prior to CKD, there are some unique procedure variables such as
”drug test(s), definitive,” ”measurement of glucose in blood,” ”nonpressurized inhalation treatment for acute airway obstruction,” ”all-inclusive clinic visit rendered in a FQHC or CHC,”
Initial hospital care, per day, for the evaluation and management of a patient; qualitative
drug screening; multiple drug classes by high complexity test method (e.g., immunoassay,
enzyme assay); antibody screening, RBC, each serum technique; blood urea nitrogen (BUN)
measurement; ”Aerobic and anaerobic blood bacterial culture,” ”measurement of sodium in
plasma,” ”measurement of aspartate amino transferase (AST) (SGOT),” ”measurement of carbon dioxide,” ”radiologic examination of the chest, single view,” ”measurement of lactate dehydrogenase (LD),” and ”blood typing; Rh (D).” These variables may be phenotypes for CKD
and may have been related to hospitalization prior to AKI.
Patients in cohort 3, one year before CKD were at risk for ’Level 4 outpatient visit for established patient with problem of moderate to high severity 25 minutes’, ’Level 3 outpatient
visit for established patient with problem of low to moderate severity 15 minutes’, ’Direct
measurement of high density cholesterol’, ’Emergency department visit for the evaluation
and management of a patient,’, ’Aerobic and anaerobic bacterial culture of blood’, ’Measurement of albumin in plasma’, ’Drug test(s), definitive,’, ’Measurement of total calcium’, ’Measurement of vitamin D 25 hydroxy’, ’Measurement of thyroid stimulating hormone (TSH)’,
’Hospital discharge day management; 30 minutes or less.’, ’Automated complete blood cell
count’.
Using similar tables available in appendix F, two and three years prior to CKD can be
similarly interpreted, and phenotypes between and within study cohorts can be considered
and analyzed.
Then, we looked at procedure variables generally throughout the three years previous
to CKD to evaluate procedure-related phenotypes and how they evolved for three research
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groups. Table 5.7’s findings reveal that between cohorts 1 and 2, ”measurement of lactate
(lactic acid)” is the sole procedural variable in common. For all individuals who had AKI
before developing CKD, this characteristic may be a phenotype for CKD. Regardless of prior
AKI,’Automated complete blood cell count (CBC) with automated differential leukocyte (WBC)
count’,’Long description: Prednisone, oral, per 5 mg Short description: Prednisone oral’,and
’Prothrombin time test’ were shared by the three groups and may all be phenotypes for CKD.
Cohort 1 had two distinct variables over the course of three years: ”Drug test(s), definite,” and
”Analysis of CO2 of blood.” For AKI patients who are hospitalized, these may be phenotypes.
Finally, There were some specific variables for cohort 3 incloudes, such as ”Measurement
of Troponin,” ”Partial thromboplastin time test on blood,” ”Level 3 outpatient visit for established patient with problem of low to moderate severity,” ”Direct measurement of high density
cholesterol,” ”Measurement of albumin in plasma,” ”Drug test(s), definitive,” ”Measurement
of vitamin D 25 hydroxy,” and ”Measurement of thyroid stimulating hormone (TSH).
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Cohort1
Drug test(s), definitive,
Long description: Prednisone, oral, per 5 mg
Short description: Prednisone oral
Measurement of lactate (lactic acid)
Measurement of glucose in blood

Cohort2
Long description: Prednisone, oral, per 5 mg
Short description: Prednisone oral

Cohort3

Non-covered item or service

Radiologic examination, chest; single view, frontal.

Electrocardiogram, routine ECG
with at least 12 leads; tracing only,
without interpretation and report
Prothrombin time test

Electrocardiogram, routine ECG with at
least 12 leads; tracing only,
without interpretation and report
Prothrombin time test
Level 4 outpatient visit for established
patient with problem of moderate to
high severity 25 minutes
Long description: Prednisone, oral,
per 5 mg Short description:
Prednisone oral
Partial thromboplastin time test on blood
Automated complete blood cell count (CBC)
with automated differential
leukocyte (WBC) count
Level 3 outpatient visit for established
patient with problem of low to
moderate severity 15 minutes

Measurement of Troponin

Nonpressurized inhalation treatment
for acute airway obstruction.

Measurement of magnesium

Automated complete blood cell count (CBC)
with automated differential leukocyte (WBC) count

Measurement of inorganic phosphorus
(phosphate)

Measurement of potassium in plasma

Partial thromboplastin time test on blood

All-inclusive clinic visit rendered
in a FQHC or CHC.

Measurement of lactate (lactic acid)

Initial hospital care, per day,
for the evaluation and management of a patient

Radiologic examination, chest;
single view, frontal.

Drug screen, qualitative;
multiple drug classes by high complexity test method
(e.g., immunoassay, enzyme assay), per patient

Measurement of Troponin

Non-covered item or service

Analysis of CO2 of blood

Automated complete blood cell count
(CBC) with automated differential
leukocyte (WBC) count

Direct measurement of high density cholesterol

Measurement of Calcium; ionized

Collection of venous blood by venipuncture

Comprehensive metabolic panel

Measurement of lactate (lactic acid)
Subsequent hospital care, per day,
for the evaluation and management
of a patient
Emergency department visit
for the evaluation
and management of a patient,
Assay of natriuretic peptide

Therapeutic procedure, one or more areas,
each 15 minutes; therapeutic exercises
to develop strength and endurance,
range of motion and flexibility
Measurement of inorganic phosphorus (phosphate)
Antibody screen, RBC, each serum technique

Collection of venous blood by
venipuncture

Blood typing; ABO

Assay of natriuretic peptide

Measurement of blood urea nitrogen (BUN)

Analysis of CO2 of blood
Therapeutic procedure, one or more areas,
each 15 minutes; therapeutic exercises to
develop strength and endurance, range of
motion and flexibility
Measurement of potassium in plasma
Subsequent hospital care, per day,
for the evaluation and management of a patient
Measurement of alanine amino transferase
(ALT) (SGPT)
Smear from primary source with
Giemsa stain for bacteria
Blood typing; ABO

Aerobic and anaerobic bacterial culture of blood
Prothrombin time test
Measurement of sodium in plasma
Measurement of aspartate
amino transferase (AST) (SGOT)
Measurement of carbon dioxide
Measurement of Calcium; ionized
Measurement of chloride in blood
Radiologic examination of chest, single view
Measurement of lactate dehydrogenase
(LD), (LDH)
Blood typing; Rh (D)

Aerobic and anaerobic
bacterial culture of blood
Measurement of albumin in plasma
Comprehensive metabolic panel
Drug test(s), definitive,
Measurement of total calcium
Measurement of vitamin D 25 hydroxy
Measurement of inorganic phosphorus
(phosphate)
Measurement of thyroid stimulating
hormone (TSH)
Measurement of magnesium
Hospital discharge day management;
30 minutes or less.
Automated complete blood cell count

Table 5.9: Year 1 procedure comparison
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Cohort1

Cohort2
Long description: Prednisone, oral, per 5 mg
Short description: Prednisone oral

Drug test(s), definitive,

Cohort3
Measurement of Troponin

Long description: Prednisone, oral, per 5 mg
Short description: Prednisone oral

Non-covered item or service

Electrocardiogram, routine ECG
with at least 12 leads; tracing only,
without interpretation and report

Measurement of lactate (lactic acid)

Electrocardiogram, routine ECG
with at least 12 leads; tracing only,
without interpretation and report

Prothrombin time test

Automated complete blood cell count (CBC)
with automated differential leukocyte (WBC) count
Analysis of CO2 of blood
Prothrombin time test

Prothrombin time test
Measurement of magnesium
Measurement of inorganic phosphorus
(phosphate)
Measurement of lactate (lactic acid)
Radiologic examination, chest;
single view, frontal.
Automated complete blood cell count (CBC)
with automated differential leukocyte (WBC) count
Comprehensive metabolic panel
Collection of venous blood by venipuncture
Subsequent hospital care, per day,
for the evaluation and management of a patient

Long description: Prednisone, oral, per 5 mg
Short description: Prednisone oral
Partial thromboplastin time test on blood
Automated complete blood cell count (CBC)
with automated differential leukocyte (WBC) count
Level 3 outpatient visit for established patient
with problem of low to moderate severity 15 minutes
Non-covered item or service
Direct measurement of high density cholesterol
Collection of venous blood by venipuncture
Subsequent hospital care, per day,
for the evaluation and management of a patient
Measurement of albumin in plasma
Comprehensive metabolic panel
Drug test(s), definitive,
Measurement of vitamin D 25 hydroxy
Measurement of thyroid stimulating hormone (TSH)

Table 5.10: Cohort comparison for procedure

5.5.3

Medications

Medicines were investigated to determine how they connected to the patient profile in the
years before CKD and generally for all research cohorts, just as the previous two sets of
diagnoses and procedures. Tables 5.8 and 5.9 were also created in order to compare and
contrast cohorts one year prior to CKD and overall. In this study, we considered 500 different medications, and now we can observe that both Cohorts 1 and 2, one year prior to
CKD, contain three significant medications. These variables are ’50 ML Albumin Human’,
’Furosemide’, and ’Magnesium Sulfate Heptahydrate’. Also, we have 10 similar variables
across all three cohorts, one year prior to CKD, which include the following: ’Ceftriaxone (as
ceftriaxone sodium)’, ’Docusate Sodium’, ’Enoxaparin Sodium’, ’Fentanyl Citrate, ’Lidocaine
Hydrochloride’, ’Ondansetron Hydrochloride’, ’Polyethylene Glycol’, ’Rocuronium Bromide’,
’Sodium Chloride ’, ’Sodium Chloride’. Cohort 1, as the only group of patients with hospitalization or inpatient visits, has unique variables, one year prior to CKD, such as ‘Heparin
Sodium’, ’Ipratropium Bromide’, ’Docusate Sodium’, ’Dextrose Monohydrate’, ’Water 100 g in
100 ml Irrigation Irrigant [veterinary sterile water for irrigation]’, ’Robinul’, ’Metformin Hydrochloride’, ’Epinephrine;Isopropyl Alcohol’, ’Bisacodyl’, ’Levofloxacin[Levaquin]’, ’Calcium
Chloride’, ’Culturelle Probiotics’, ’Ondansetron’, ’Product Containing Precisely Prochlorperazine Maleate’. moreover, cohort 3, as the only cohort with patients who have never experienced AKI, has unique variables, one year prior to CKD, like ’Dexamethasone Sodium Phosphate’, ’Robinul’, ’Ephedrine Sulfate ’, ’Amoxicillin’, ’Lorazepam’, ’Trazodone Hydrochloride’,
’Donepezil Hydrochloride’, ’Nicotine’, ’Oxycodone Hydrochloride’, ’Hydrocodone Bitartrate’,
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’Docusate Sodium’, ”Heparin Sodium’, ’Prednisone[Deltasone]’.
Similarity and dissimilarity between various cohorts two and three years prior to CKD,
as well as one year prior to CKD, are taken into account using similar tables in the appendix
F.
Then we compared three cohorts over the three years preceding CKD, and the only similarity between cohorts 1 and 2 was ‘Magnesium Sulfate Heptahydrate’, which belonged to
the year preceding CKD. Similarly, for three years, eight medications were shared among
three cohorts. Those variables are ’Ceftriaxone (as ceftriaxone sodium) 1 g powder for solution for injection vial’, ’Docusate Sodium’, ’Enoxaparin Sodium’, ’Fentanyl Citrate’, ’Lidocaine
Hydrochloride’, ’Ondansetron Hydrochloride’, ’Sodium Chloride’, ’Sodium Chloride’.
The medications that were unique in cohort 1 during three years prior to CKD were ‘Heparin Sodium’, ’Ipratropium Bromide’, ’Furosemide’, ’Polyethylene Glycol’. These medications
can be phenotypes related to hospitalization or an inpatient visit prior to AKI. ’Dexamethasone Sodium Phosphate’, ’Hydrocodone Bitartrate’, ’Docusate Sodium’, ‘Heparin Sodium’
were specific medications taken by cohort 3 over the course of three years that could be
considered phenotypes but were not linked to AKI.
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Cohort1
Sodium Chloride
Ondansetron Hydrochloride
Fentanyl Citrate

Ipratropium Bromide

Cohort2
Fentanyl Citrate
Sodium Chloride
Acetaminophen
Ondansetron
Hydrochloride[ondansetron]
Sodium Chloride

Ceftriaxone (as Ceftriaxone Codium)

Ceftriaxone (as Ceftriaxone Sodium)

Docusate Sodium

Docusate Sodium
Furosemide
Polyethylene Glycol

Polyethylene glycol
Magnesium Sulfate
Heptahydrate [Magnesium Sulfate in Water]#4
Docusate Sodium[senna-s]
Furosemide
50 ml Albumin Human

Sodium Chloride

Rocuronium Bromide

Magnesium Sulfate Heptahydrate
Enoxaparin Sodium

Sodium Chloride
Famotidine

Lidocaine Hydrochloride

2 ml Sugammadex

Rocuronium Bromide

Chlorhexidine Gluconate

Acetaminophen
Sodium Chloride
Lorazepam
Ondansetron
Hydrochloride [Ondansetron]
Trazodone Hydrochloride
Ceftriaxone (as Ceftriaxone Sodium)
Donepezil Hydrochloride
[Donepezil Hydrochloride]
Nicotine
[Nicotine Transdermal System Step 1]

Flagyl

Oxycodone Hydrochloride

Enoxaparin Sodium

Hydrocodone Bitartrate
Docusate Sodium
Heparin Sodium
Prednisone [Deltasone]
Docusate Sodium
Enoxaparin Sodium

Heparin Sodium

Dextrose Monohydrate

Water/ Irrigation Irrigant
[veterinary sterile water for irrigation]
Robinul
50 ml Albumin Human
Metformin Hydrochloride
Epinephrine; Isopropyl Alcohol
Bisacodyl
Levofloxacin
Calcium Chloride
Culturelle Probiotics
15 Billion CFU Capsule
Ondansetron [Zofran]
Product Containing Precisely Prochlorperazine Maleate

Lidocaine Hydrochloride

Cohort3
Sodium Chloride
Lidocaine Hydrochloride
Dexamethasone Sodium Phosphate
Fentanyl Citrate
Robinul
Ephedrine Sulfate
[Premierpro Rx Ephedrine Sulfate]
Amoxicillin
Rocuronium Bromide

Polyethylene Glycol

Table 5.11: Year 1 medication comparison
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Cohort1
Sodium Chloride
Ondansetron
Hydrochloride [ondansetron]
Fentanyl Citrate
Heparin Sodium
Ipratropium Bromide
Ceftriaxone (as Ceftriaxone Sodium)
Docusate Sodium
Furosemide
Polyethylene Glycol
Sodium Chloride [Veterinary Lactated]
Magnesium Sulfate
Heptahydrate
[Magnesium Sulfate in Water] #4
Enoxaparin Sodium
Lidocaine Hydrochloride

Cohort2
Fentanyl Citrate
Sodium Chloride
[veterinary lactated]
Acetaminophen
Ondansetron
Hydrochloride [ondansetron]
Sodium Chloride
Ceftriaxone (as Ceftriaxone Sodium)
Magnesium Sulfate Heptahydrate
[Magnesium Sulfate in Water] #4
Docusate Sodium
Rocuronium Bromide
Enoxaparin Sodium

Cohort3
Sodium Chloride[Veterinary Lactated]
Lidocaine
Hydrochloride
Dexamethasone Sodium Phosphate
Fentanyl Citrate
Acetaminophen
Sodium Chloride
Ondansetron
Hydrochloride [Ondansetron]
Ceftriaxone (as Ceftriaxone Sodium)
Hydrocodone Bitartrate
Docusate Sodium
Heparin Sodium

Lidocaine Hydrochloride
Docusate Sodium
Enoxaparin Sodium

Table 5.12: Cohort comparison for medications

5.5.4

Lab results

In this study, lab data were also taken into account to identify individuals who had high levels
of anomalies across several lab identifiers. Finding risk variables in this section is crucial since
lab tests are one of the most crucial diagnostic tools for CKD. As part of our work, we gathered
important lab variables during each year for each cohort. Tables 5.10 shows this information
for one year prior to CKD. Similar tables are available for the two and three years prior to
CKD in the appendix F. Then we compared different cohorts during different years prior to
CKD based on the similarity and dissimilarity of variables between cohorts.
For one year prior to CKD, based on table 5.10, we see that there is no similarity between
cohorts 1 and 2 in the year 1, which we could relate to patients with prior AKI only. However,
we see the similarity between three cohorts during the year prior to CKD. These similarities
are due to common variables such as ’Alkaline phosphatase Enzymatic.activity volume in
Serum Plasma or Blood’,’Bilirubin total Mass volume in Serum Plasma or Blood’,’Folate Mass
volume in Serum Plasma or Blood’ ,’Glucose’, ’Hematocrit’ ,’Hemoglobin A1c Hemoglobin total in Blood’ ,’Hepatitis B virus surface Ab Units volume in Serum’ ,’Platelets’ ,’Urea nitrogen
Mass volume in Serum Plasma or Blood’ , and ’White blood cell Leukocytes volume in Blood’.
Additionally, there were no specific lab tests for Cohort 1 to demonstrate if it might be connected to inpatient stays or hospitalizations. Cohort 3 was the only cohort without AKI, and
it only had one distinctive variable—protein mass volume in serum or plasma, one year prior
to CKD.
For cohort comparison during the three years, as table 5.11 shows, the only similarity
between cohorts 1 and 2 was ”glucose,” which can be related to AKI prior to CKD. Among
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the three cohorts, we see that ”hematocrit,” ”platelets,” ”urea nitrogen mass volume in serum
plasma or blood,” and ”white blood cell leukocyte volume in blood” were common during the
three years prior to CKD. These factors can be phenotypes for CKD without being related
to AKI. ”Bilirubin total mass volume in serum plasma or blood,” ”Alkaline phosphatase enzymatic activity volume in serum plasma or blood,” ”Folate mass volume in serum plasma
or blood,” and ”Hemoglobin A1c hemoglobin total in blood” are unique variables in cohort
1, which may be related to hospitalization and inpatient visits, and Alkaline phosphatase
Enzymatic activity volume in serum, plasma, or blood, hemoglobin A1c, hemoglobin total in
blood, and protein mass volume in serum or plasma were unique variables in cohort 3, the
only cohort without prior AKI.
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Cohort1
White blood cell Leukocytes
volume in Blood
Hepatitis B virus surface
Ab Units volume in Serum

Cohort2
White blood cell Leukocytes
volume in Blood
Hematocrit

Platelets

Urea nitrogen Mass volume
in Serum Plasma or Blood

Bilirubin total Mass volume
in Serum Plasma or Blood

Platelets

Glucose
Hematocrit
Alkaline phosphatase
Enzymatic activity volume
in Serum Plasma or Blood
Urea nitrogen Mass
volume in Serum
Plasma or Blood
Folate Mass volume in
Serum Plasma or Blood
Hemoglobin A1c
Hemoglobin total in Blood

Hemoglobin A1c
Hemoglobin total in Blood
Alkaline phosphatase Enzymatic
activity volume in
Serum Plasma or Blood

Platelets
Urea nitrogen Mass volume
in Serum Plasma or Blood
Alkaline phosphatase
Enzymatic activity volume
in Serum Plasma or Blood
Hemoglobin A1c
Hemoglobin total in Blood
Glucose
Hepatitis B virus surface Ab
Units volume in Serum

Folate Mass volume in Serum
Plasma or Blood

Hematocrit

Glucose

Bilirubin total Mass volume
in Serum Plasma or Blood

Hepatitis B virus surface Ab
Units volume in Serum
Bilirubin total Mass volume
in Serum Plasma or Blood

Table 5.13: Year 1 lab comparison
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Cohort3

White blood cell Leukocytes
volume in Blood
Protein Mass volume
in Serum or Plasma
Folate Mass volume
in Serum Plasma or Blood

5.5. Cohort comparison and insights

Cohort1

Cohort2

White blood cell Leukocytes

White blood cell Leukocytes

volume in Blood

volume in Blood

Platelets

Hematocrit

Bilirubin total Mass volume

Urea nitrogen Mass volume

in Serum Plasma or Blood

in Serum Plasma or Blood

Glucose

Platelets

Hematocrit

Glucose

Hematocrit

Hepatitis B virus surface Ab

White blood cell Leukocytes

Units volume in Serum

volume in Blood

Alkaline phosphatase Enzymatic
activity volume
in Serum Plasma or Blood

Cohort3
Platelets
Urea nitrogen Mass volume
in Serum Plasma or Blood
Alkaline phosphatase
Enzymatic activity volume
in Serum Plasma or Blood
Hemoglobin A1c
Hemoglobin total in Blood

Urea nitrogen Mass volume in

Protein Mass volume

Serum Plasma or Blood

in Serum or Plasma

Folate Mass volume
in Serum Plasma or Blood
Hemoglobin A1c
Hemoglobin total in Blood
Table 5.14: Cohort comparison for lab

5.5.5

Vital Signs

This section examines whether or not particular vital signs were crucial for the three research
groups in the 1, 2, and 3 years prior to CKD. We identified five vital sign variables, and as tables
5.20, 5.21, and 5.22 demonstrate, they were significant criteria in the three years before CKD
because patients had abnormal values for these criteria. We may argue that these factors were
equally important criterion for all cohorts because they occurred for all cohorts throughout
all years.
There was no specific vital sign between cohorts 1 and 2 related to AKI; however, there
were three common vital signs between the three cohorts during the three years in the cloud:
”blood pressure systolic,” ”body temperature,” and ”heart rate.” related to CKD only. BMI for
cohort 2 and blood pressure diastolic for cohort 1 were not phenotypes.
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Cohort1

Cohort2

Cohort3

Body temperature

Heart rate

Body temperature

BMI

Blood Pressure Diastolic

Blood Pressure Diastolic

Blood Pressure Diastolic

Body temperature

Blood Pressure Systolic

Blood Pressure Systolic

Blood Pressure Systolic

BMI

Heart rate

BMI

Heart rate

Table 5.15: Year 1 vital sign comparison

Cohort1

Cohort2

Cohort3

Body temperature

Heart rate

Body temperature

BMI

Blood Pressure Diastolic

Blood Pressure Diastolic

Blood Pressure Systolic

Body temperature

Blood Pressure Systolic

Heart rate

Blood Pressure Systolic

BMI
Heart rate

Table 5.16: Cohort comparison for vital signs
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Discussion

A total of 75033 CKD patients were considered. Patients with AKI after CKD are excluded
from this study. Otherwise, they had been classified into three study cohorts with different
clinical characteristics. Cohort 1 includes 7442 patients who had AKI within 90 days of hospitalization prior to 3 years of CKD. Cohort 2 includes 6408 patients those with AKI who were
not hospitalized within 90 days prior to 3 years of CKD, as well as those with AKI prior to 5
years of CKD who were not in Cohort 1, and cohort 3 with 39280 CKD patients with never
experienced AKI. The clinical characteristics of patients in cohorts 1 and 2 and cohort 3 had
been considered in terms of identifying the effects of AKI and hospitalization on CKD. Age
and BMI, white ethnicity, as well as comorbidities listed in Table 5.1, are considered significant variables. Gender is considered significant for Cohort 1.
Variables are chosen in two steps: the first is based on clinical expert opinion, and the
second is based on data mining methodology. A clinical expert selected the diagnosis, procedures, medications, lab results, and vital signs. Top variables were selected from the datasets,
and then, using data mining methods, the most important variables were selected based on
MDA and the prevalence of the variables.
K-means and LCA methods were selected to group patients in each cohort, year by year,
during the 3 years before CKD. K-means was selected as one of the most widely used clustering algorithms because it is fast for big data and easy to understand. LCA, as a model-based
method, is more interpretable and preferred in healthcare analysis and was selected to apply
to the datasets. Patients’ assignment by each clustering method was compared. As a result,
K-means clusters were identified pretty close to LCA clusters. The LCA clusters are chosen for
data analysis because it is considered to be more reliable method compared to the K-means
for generating meaningful clusters from high dimensional binary data.
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The clustering of patients showed different phenotypes in each cluster for each year
within a cohort with the same clinical characteristics. which shows the importance of clustering. The high similarity between phenotypes in each cluster prevents us from naming the
clusters.
Similarity between years is calculated to determine whether patients in a cohort change
their groups over time. Because of the low similarity between patient groups, we decided to
compare patient profiles in three cohorts on a yearly basis. Variable similarity and dissimilarity between cohorts are evaluated and interpreted on a yearly basis based on their health
characteristics. Similarly, comparisons of variables between cohorts had been considered and
interpreted.

6.2

Strengths of the study

This research analyzed high-dimensional clinical data for three large cohorts of patients with
different health characteristics. Phenotypes for a patient were studied for years, even up to
three years before CKD, to see how they changed over time. Also, the roles of diagnosis,
procedures, medication, lab results, and vital signs have been considered separately.

6.3

Limitation of the study

The absence of non-CKD patients prevents us from developing an algorithm for predicting
health outcomes in the CKD and non-CKD groups. Also, as this study was done on CKD
patients in West Virginia and thus limited to a particular geographic region, it may not be
generalized to all CKD patients.

6.4

Contributions

A clustering-based patient profiling system has been developed where we can find time-based
phenotypes for a patient and use them to understand the patient’s journey from AKI to CKD.
Then, two existing methods were compared to determine which was superior. The results
show there are numerous phenotypes that may impact or contribute to CKD.

6.5

Future works

One of our research objectives was to develop AI tools, but we could not do that because of
the scale of the data we had. Applying AI to data with a large number of variables will take
much more time, which is beyond the scope of this thesis. AI tools will be developed in the
future and validated by the clustering results obtained by this research.
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Important phenotypes obtained from this study can be used in the future to predict CKD
patients in various study cohorts generally and across years differently based on diagnosis,
procedures, medications, lab results, and vital signs.

6.6

Conclusions

The findings from clustering suggests that phenotypes are different for different classes of
patients, so a single care method doesn’t work for all patients. Categorizing patients into
distinct groups allows for the allocation of different resources and strategies for the care of
different groups of patients.
According to the results of the Jaccard similarity test, patient profiles change in the years
before developing CKD; hence, research cohorts need to take each year into account in order
to identify the phenotypes.
Three research cohorts’ key factors were compared annually and generally, and the results
revealed some similarities as well as some differences across the cohorts for each year. These
findings suggest that specific CKD phenotypes may be linked to prior AKI, hospitalization,
inpatient care, and CKD regardless of prior AKI.
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A
The number of principal components needed for logistic PCA to keep 80% of the variance of
the original dataset.
a. Cohort 2

(a)

(b)

(c)

Figure A.1: The number of principal components for cohort 2. (a) year 1; (b) year 2; (c) year 3 .
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b. Cohort 3

(a)

(b)

(c)

Figure A.2: The number of principal components for cohort 3. (a) year 1; (b) year 2; (c) year 3 .
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B
The elbow method demonstrates the best number of clusters (k) for K-means.
a. Cohort 2

(a)

(b)

(c)

Figure B.1: The elbow method to find the number of clusters for cohort 2. (a) year 1; (b) year 2; (c)
year 3 .
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b. Cohort 3

(a)

(b)

(c)

Figure B.2: The elbow method to find the number of clusters for cohort 3. (a) year 1; (b) year 2; (c)
year 3 .
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C
Visualizing clusters of K-means
a. Cohort 2

(a)

(b)

(c)

Figure C.1: Clusters of K-means for cohort 2. (a) year 1; (b) year 2; (c) year 3 .

To visualize K-means clustering, data points are projected on two axes; the values on the x
and y axes are connected to these two PCs and do not exhibit a distinctive variable.
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b. Cohort 3

(a)

(b)

(c)

Figure C.2: Clusters of K-means for cohort 3. (a) year 1; (b) year 2; (c) year 3.

To visualize K-means clustering, data points are projected on two axes; the values on the x
and y axes are connected to these two PCs and do not exhibit a distinctive variable.
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D
Comparison of k-means clustering with latent class analysis(LCA)
a. Cohort 2
1. Year 1 Cohort 2

(a)

(b)

(c)

(d)

Figure D.1: Comparison of K-means clustering with latent class analysis(LCA) in year 1 cohort 2
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2. Year 2 Cohort 2

(a)

(b)

(c)

(d)

(e)

Figure D.2: Comparison of K-means clustering with latent class analysis(LCA) in year 2 cohort 2
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3. Year 3 Cohort 2

(a)

(b)

(c)

(d)

Figure D.3: Comparison of K-means clustering with latent class analysis(LCA) in year 3 cohort 2
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b. Cohort 3
1. Year 1 Cohort 3

(a)

(b)

(c)

(d)

(e)

(f)

Figure D.4: Comparison of K-means clustering with latent class analysis(LCA) in year 1 cohort 3
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2. Year 2 Cohort 3

(a)

(b)

(c)

(d)

Figure D.5: Comparison of K-means clustering with latent class analysis(LCA) in year 2 cohort 3
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3. Year 3 Cohort 3

(a)

(b)

(c)

(d)

Figure D.6: Comparison of K-means clustering with latent class analysis(LCA) in year 3 cohort 3
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E
Jaccard similarity index
a. Cohort 2

(a)

(b)

(c)

Figure E.1: Jaccard similarity index for cohort 2. (a) year 1; (b) year 2; (c) year 3 .
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b. Cohort 3

(a)

(b)

(c)

Figure E.2: Jaccard similarity index for cohort 3. (a) year 1; (b) year 2; (c) year 3 .
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F
Important variables based on MDA
a. Diagnosis
1. Year 2
Cohort1

Cohort2

Cohort3

Hypertensive diseases

Abnormalities of breathing

Long term (current) use of anticoagulants

Other long term (current) drug therapy

Abnormal electrocardiogram[ECG] [EKG]

Long term (current)use of aspirin

Long term (current) use of aspirin

Hypertensive diseases

Encounter for other

Disorders of lipoprotein

preprocedural examination

metabolism and other lipidemias

Abnormalities of breathing

Low back pain

Other long term (current) drug therapy

Osteoarthritis

Atrial fibrillation and flutter

Disease of the blood and blood forming organs

Abnormal electrocardiogram

Atherosclerotic heart disease

[ECG] [EKG]

of native coronary artery without angina pectoris

Other long term (current)
drug therapy

Chronic ischemic heart disease

Other specified

Cardiomegaly

Bradycardia, unspecified

Weakness

Major depressive disorder,

Disorders of lipoprotein

Atherosclerotic heart disease

single episode, unspecified

metabolism and other lipidemias

of native coronary artery without angina pectoris

Encounter for other

Abnormal electrocardiogram

Long term (current) use

preprocedural examination

[ECG] [EKG]

of anticoagulants

Cardiomegaly

Encounter for immunization

postprocedural states

Disorders of lipoprotein
metabolism and other lipidemias

Encounter for general

Hypertensive diseases

Type 2 diabetes mellitus

Other fatigue

Weakness

Hypothyroidism

Encounter for immunization

Type 2 diabetes mellitus

Chest pain, unspecified

Other chronic pain

Encounter for immunization

Hyperkalemia

Other fatigue

Encounter for screening for malignant neoplasm of colon

Pleural effusion

Overweight and obesity

Overweight and obesity

Overweight and obesity

Encounter for general adult medical examination
without abnormal findings
Encounter for screening
mammogram for malignant neoplasm of breast

Encounter for general adult medical examination

Hypothyroidism

without abnormal findings
Disease of the blood

Unspecified abdominal pain

and blood forming organs

adult medical examination without abnormal findings

Encounter for screening
for malignant neoplasm of colon
Vitamin D deficiency, unspecified
Cough

Chest pain, unspecified

Major depressive disorder,single episode, unspecified

Encounter for other preprocedural examination

Atrial fibrillation and flutter

Other chronic pain

Other specified postprocedural states

Hypokalemia

Chronic obstructive pulmonary disease

Low back pain

Long term (current) use of

Encounter for screening

anticoagulants

mammogram for malignant neoplasm of breast

Localized edema
Dorsalgia, unspecified

Anxiety disorders

Diarrhea, unspecified

Constipation, unspecified

Encounter for follow-up examination after completed
treatment for conditions

Abnormalities of breathing

other than malignant neoplasm
Edema, unspecified

Other specified postprocedural states

Other specified soft tissue disorders

Hypokalemia

Other chronic pain
Atherosclerotic heart disease
of native coronary artery without angina pectoris
Cardiomegaly

Table F.1: Year 2 diagnosis comparison
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2. Year 3
Cohort1

Cohort2

Disorders of lipoprotein metabolism

Hypertensive diseases

and other lipidemias
Hypertensive diseases
Other long term (current) drug therapy
Encounter for immunization

Other long term (current)
drug therapy

Bradycardia, unspecified

Hypertensive diseases

Abnormal electrocardiogram

Disorders of lipoprotein metabolism

[ECG] [EKG]

and other lipidemias

Other long term (current) drug therapy

Abnormalities of breathing

Disorders of lipoprotein metabolism

Long term (current) use of aspirin

Cohort3

and other lipidemias

Anxiety disorders

Type 2 diabetes mellitus

Abnormalities of breathing

Abnormal electrocardiogram [ECG] [EKG]

Urinary tract infection, site not specified

Chest pain, unspecified

Overweight and obesity

Overweight and obesity

Disease of the blood and blood forming organs

Long term (current) use of anticoagulants

Vitamin D deficiency, unspecified

Long term (current) use of anticoagulants

Encounter for other preprocedural examination

Major depressive disorder,

Atherosclerotic heart disease of native

single episode, unspecified

coronary artery without angina pectoris

Osteoarthritis
Atherosclerotic heart disease of native

Long term (current) use of aspirin

coronary artery without angina pectoris
Hypothyroidism

Type 2 diabetes mellitus

Encounter for general adult medical

Major depressive disorder,
single episode, unspecified
Encounter for general adult medical
examination without abnormal findings

Chronic obstructive pulmonary disease

Encounter for immunization

Disease of the blood and blood forming organs

Encounter for immunization

Hypothyroidism

Hypokalemia

Overweight and obesity

Type 2 diabetes mellitus

Atherosclerotic heart disease of

Encounter for screening mammogram

native coronary artery without angina pectoris

for malignant neoplasm of breast

Cardiomegaly

Other specified postprocedural states

Cough

Abnormal electrocardiogram [ECG] [EKG]

Osteoarthritis

Vitamin D deficiency, unspecified

Diarrhea, unspecified

Unspecified abdominal pain

Other fatigue

Chronic ischemic heart disease

Pleural effusion

Disease of the blood and blood forming organs

Encounter for other preprocedural examination

Weakness

Other specified postprocedural states

Hyperkalemia

Weakness

Nonrheumatic mitral (valve) insufficiency

examination without abnormal findings

Nonrheumatic mitral (valve) insufficiency

Major depressive disorder,
single episode, unspecified

Encounter for screening for
malignant neoplasm of colon

Hypokalemia

Abnormalities of breathing
Chronic obstructive pulmonary disease
Chest pain, unspecified
Anxiety disorders

Table F.2: Year 3 diagnosis comparison
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Chapter F

b. Procedures
1. Year 2
Cohort1

Cohort2

Cohort3

Automated complete blood cell count (CBC)

Electrocardiogram, routine ECG with at least 12 leads;

Initial hospital care, per day, for the e

with automated differential leukocyte (WBC) count

tracing only, without interpretation and report

valuation and management of a patient

Measurement of albumin in plasma

Measurement of Troponin

Radiologic examination, chest; single view, frontal.

Long description: Prednisone, oral,

Drug test(s), definitive,

per 5 mg Short description: Prednisone oral

Long description: Prednisone, oral,

Automated complete blood cell count (CBC)

per 5 mg Short description: Prednisone oral

with automated differential leukocyte (WBC) count

Comprehensive metabolic panel

Measurement of magnesium
Measurement of inorganic phosphorus (phosphate)

Radiologic examination, chest;

Subsequent hospital care, per day,

single view, frontal.

for the evaluation and management of a patient

Prothrombin time test

Prothrombin time test

Drug test(s), definitive,

Non-covered item or service

Non-covered item or service

Partial thromboplastin time test on blood

Electrocardiogram, routine ECG with at least
12 leads; tracing only,
without interpretation and report
Measurement of total calcium
Therapeutic procedure, one or more areas,
each 15 minutes; therapeutic exercises to
develop strength and endurance, range of
motion and flexibility
Electrocardiogram, routine ECG with at least

Automated urinalysis using dip

Comprehensive metabolic panel

stick and microscopy of urine

12 leads; tracing only,
without interpretation and report

Measurement of Troponin

Partial thromboplastin time test on blood

Collection of venous blood by venipuncture

Collection of venous blood by venipuncture
Subsequent hospital care, per day,

Direct measurement of high density cholesterol

for the evaluation and management of a patient

Long description: Prednisone, oral,
per 5 mg Short description: Prednisone oral
Automated complete blood cell count (CBC)
with automated differential leukocyte (WBC) count
Collection of venous blood by venipuncture

Level 4 outpatient visit for established patient

Initial hospital care, per day, for the

with problem of moderate to high severity 25 minutes

evaluation and management of a patient

Measurement of thyroid stimulating hormone (TSH)

Aerobic and anaerobic bacterial culture of blood

Comprehensive metabolic panel

Non-covered item or service

Measurement of magnesium

Direct measurement of high density cholesterol

Measurement of total bilirubin

Measurement of lactate (lactic acid)

Measurement of thyroid stimulating hormone (TSH)

Measurement of vitamin D 25 hydroxy
Measurement of magnesium

Level 4 outpatient visit for established patient
with problem of moderate to high severity 25 minutes
Level 3 outpatient visit for established patient
with problem of low to moderate severity 15 minutes

Drug test(s), definitive,

Measurement of glycosylated hemoglobin (HbA1C)
Measurement of albumin in plasma
Automated urinalysis using dip stick and

Prothrombin time test

Direct measurement of high density cholesterol

Partial thromboplastin time test on blood

Measurement of glycosylated hemoglobin (HbA1C)

Measurement of lactate (lactic acid)

Measurement of total calcium

Radiologic examination, chest;

Measurement of inorganic phosphorus

Level 3 outpatient visit for established patient

single view, frontal.

(phosphate)

with problem of low to moderate severity 15 minutes

Analysis of CO2 of blood

Automated complete blood cell count

Measurement of Troponin

microscopy of urine
Influenza immunization administered
Level 4 outpatient visit for established patient
with problem of moderate to high severity 25 minutes

Postoperative follow-up visit,
included in global service.
Measurement of total calcium
Measurement of vitamin D 25 hydroxy

Table F.3: Year 2 procedure comparison
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2. Year 3
Cohort1

Cohort2

Cohort3

Automated complete blood cell count (CBC)

Automated urinalysis using dip

Long description: Prednisone, oral,

with automated differential leukocyte (WBC) count

stick and microscopy of urine

per 5 mg Short description: Prednisone oral

Measurement of potassium in plasma

Non-covered item or service

Collection of venous blood

Hospital discharge day management;

Automated complete blood cell count (CBC)

by venipuncture

30 minutes or less.

with automated differential leukocyte (WBC) count

Long description: Prednisone, oral,
per 5 mg Short description: Prednisone oral

Direct measurement of

Collection of venous blood by venipuncture

high density cholesterol

Electrocardiogram, routine ECG with at least
12 leads; tracing only, without interpretation and report

Comprehensive metabolic panel

Radiologic examination, chest; single view, frontal.

Drug test(s), definitive,

Drug test(s), definitive,

Measurement of direct bilirubin

Partial thromboplastin time test on blood

Measurement of lactate (lactic acid)

Measurement of Troponin

Non-covered item or service

Measurement of magnesium

Collection of venous blood by venipuncture

Measurement of total calcium

Measurement of alkaline phosphatase

Electrocardiogram, routine ECG with at least
12 leads; tracing only, without interpretation and report

Prothrombin time test
Measurement of glycosylated hemoglobin (HbA1C)
Level 3 outpatient visit for established patient
with problem of low to moderate severity 15 minutes
Measurement of inorganic phosphorus (phosphate)
Initial hospital care, per day, for the
evaluation and management of a patient
Measurement of lactate (lactic acid)
Analysis of CO2 of blood

Automated urinalysis using dip

transferase (AST) (SGOT)

stick and microscopy of urine

Measurement of inorganic phosphorus (phosphate)

Direct measurement of high density cholesterol

Non-covered item or service

Prothrombin time test

Prothrombin time test

Measurement of thyroid stimulating hormone (TSH)

Drug test(s), definitive,

Comprehensive metabolic panel

Subsequent hospital care, per day, for the
evaluation and management of a patient

Level 3 outpatient visit for established patient

evaluation and management of a patient

with problem of low to moderate severity 15 minutes

evaluation and management of a patient

per 5 mg Short description: Prednisone oral

for the evaluation and management of a patient,
Measurement of sodium in plasma
Aerobic and anaerobic bacterial culture of blood
Automated urinalysis using
dip stick and microscopy of urine
Measurement of total bilirubin
Measurement of magnesium
Measurement of Troponin

Influenza immunization administered

Initial hospital care, per day, for the
Long description: Prednisone, oral,

Subsequent hospital care, per day,

12 leads; interpretation and report only.

Measurement of aspartate amino

Subsequent hospital care, per day, for the

Measurement of chloride in blood

Electrocardiogram, routine ECG with at least

Measurement of glycosylated hemoglobin (HbA1C)

Automated complete blood cell count (CBC)

Subsequent hospital care, per day, for the

with automated differential leukocyte (WBC) count

evaluation and management of a patient

Comprehensive metabolic panel
Measurement of glycosylated hemoglobin (HbA1C)
Electrocardiogram, routine ECG with at least
12 leads; tracing only, without interpretation and report
Measurement of thyroid stimulating hormone (TSH)

Hospital discharge day management;
30 minutes or less.
Measurement of albumin in plasma
Measurement of creatinine in blood
Measurement of vitamin D 25 hydroxy

Level 4 outpatient visit for established patient
with problem of moderate to high severity 25 minutes
Level 3 outpatient visit for established patient
with problem of low to moderate severity 15 minutes
Level 2 outpatient visit for evaluation a
established patient 10 minutes or less

Electrocardiogram, routine ECG with at least

Subsequent hospital care, per day, for the

12 leads; interpretation and report only.

evaluation and management of a patient,
Measurement of Calcium; ionized
Continuous positive airway pressure
ventilation (CPAP), initiation and management

Table F.4: Year 3 procedure comparison
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Chapter F

c. Medications
1. Year 2
Cohort1

Cohort2

Cohort3

Ceftriaxone (as Ceftriaxone Sodium)

Rocuronium Bromide

Heparin Sodium

Fentanyl Citrate

Lidocaine Hydrochloride

Ondansetron Hydrochloride [Ondansetron]

50 ml Albumin Human

Sodium Chloride

Hydromorphone HCL

Fentanyl Citrate

2 ml Sugammadex

Docusate Dodium

Sodium Chloride [Veterinary Lactated]

Dexamethasone Sodium Phosphate

Polyethylene Glycol

Docusate Sodium

Acetaminophen

Enoxaparin Sodium

Ondansetron Hydrochloride
[Ondansetron]
Sodium Chloride
Magnesium Sulfate Heptahydrate
[Magnesium Sulfate in Water] #4

Ephedrine Sulfate

Furosemide

[Premierpro RX Ephedrine Sulfate]

Docusate Sodium

Heparin Sodium

Sodium Chloride[Veterinary Lactated]

Furosemide

Enoxaparin Sodium

Robinul

Ceftriaxone (as Ceftriaxone Sodium)

Polyethylene Glycol

Fentanyl Citrate

Sodium Chloride [Veterinary Lactated]

Ipratropium Bromide

Sodium Chloride

Ipratropium Bromide

Ondansetron Hydrochloride

Dextrose Monohydrate

[Ondansetron]
Donepezil Hydrochloride

Nitroglycerin

[Donepezil Hydrochloride]

Epinephrine;isopropyl Alcohol

Famotidine
Phillips Milk of Magnesia

Oxycodone Hydrochloride

Calcium Chloride

Hydrocodone Bitartrate

Acetaminophen

Ceftriaxone (as Ceftriaxone Sodium)

Dexamethasone Sodium Phosphate

50 ml Albumin Human

Omeprazole

0.5 ml Hydromorphone Hydrochloride

Pregabalin

Metformin Hydrochloride

Hydrocodone Bitartrate

[Epinephrinesnap-v]
Chlorhexidine Gluconate
Product Containing Precisely Oxycodone
Hydrochloride (Clinical Drug)

Calcium Chloride
Levalbuterol Hydrochloride

Meclizine Hydrochloride
[Meclizine Hydrochloride]
Magnesium Sulfate Heptahydrate
[Magnesium Sulfate in Water] #4

Lidocaine

Zocor

Lidocaine Hydrochloride

Tetracaine Hydrochloride

Lidocaine Hydrochloride

Furosemide
Heparin Sodium
Rocuronium Bromide

Docusate Sodium
Morphine Sulfate
Enoxaparin Sodium

Table F.5: Year 2 medication comparison
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2. Year 3
Cohort1

Cohort2

Cohort3

Sodium Chloride

Atropine Sulfate

Ondansetron Hydrochloride

Ondansetron Hydrochloride

Buspirone Hydrochloride

Fentanyl Citrate

Fentanyl Citrate

Ondansetron

Sodium Chloride

Sodium Chloride

Montelukast

Ceftriaxone (as Ceftriaxone Sodium)

Hydrocodone Bitartrate

Phenol

Docusate Sodium

Nitroglycerin

Flagyl

Rocuronium Bromide

Furosemide

Sucralfate [Carafate]

Docusate Sodium

Heparin Sodium

Remeron

Sodium Chloride

Ceftriaxone (as Ceftriaxone Sodium)

Pregabalin

Dexamethasone Sodium Phosphate

Ipratropium Bromide

Esomeprazole Magnesium

Lidocaine Hydrochloride

Sodium Chloride

Enoxaparin Sodium

Polyethylene Glycol

Docusate Sodium

Acetaminophen

Phillips Milk of Magnesia

Ondansetron Hydrochloride [Ondansetron]

Phillips Milk of Magnesia

Piperacillin Sodium

Fentanyl Citrate

Bisacodyl

Lidocaine Hydrochloride

Morphine Sulfate

Famotidine

Dexamethasone Sodium Phosphate

Sodium Chloride [Veterinary Lactated]

Morphine Sulfate

Enoxaparin Sodium

Docusate Sodium

Docusate Sodium

Famotidine

Hydralazine Hydrochloride

Enoxaparin Sodium

Heparin Sodium

Rocuronium Bromide

Hydrocodone Bitartrate

Ceftriaxone (as Ceftriaxone Sodium)

Lorazepam

Magnesium Sulfate Heptahydrate
[Magnesium Sulfate in Water] #4

Magnesium Sulfate Heptahydrate
[Magnesium Sulfate in Water] #4

Lidocaine Hydrochloride
Dexamethasone Sodium Phosphate
Magnesium Sulfate Heptahydrate
[Magnesium Sulfate in Water] #4
Ergocalciferol
Ropinirole
Methylprednisolone Acetate
Piperacillin Sodium
Lamictal
Tizanidine [Zanaflex]
Magnesium Sulfate Heptahydrate
[Magnesium Sulfate in Water] #3
Acetaminophen

Table F.6: Year 3 medication comparison
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Chapter F

d. Labs
1. Year 2
Cohort1

Cohort2

Platelets

Platelets

Hepatitis B virus surface Ab

Hemoglobin A1c Hemoglobin

Bilirubin.total Mass volume

Units volume in Serum

total in Blood

in Serum Plasma or Blood

Protein Mass volume in

Protein Mass volume

Protein Mass volume

Serum or Plasma

in Serum or Plasma

in Serum or Plasma

Hepatitis B virus surface Ab

Hepatitis B virus surface Ab

Units volume in Serum

Units volume in Serum

Bilirubin total Mass volume

Folate Mass volume

Alkaline phosphatase Enzymatic

in Serum Plasma or Blood

in Serum Plasma or Blood

activity volume in Serum Plasma or Blood

White blood cell Leukocytes

Alkaline phosphatase Enzymatic

Urea nitrogen Mass volume

volume in Blood

activity volume in Serum Plasma or Blood

in Serum Plasma or Blood

Hemoglobin A1c Hemoglobin

Urea nitrogen Mass volume

total in Blood

in Serum Plasma or Blood

Glucose

Urea nitrogen Mass volume
in Serum Plasma or Blood
Alkaline phosphatase
Enzymatic activity volume
in Serum Plasma or Blood
Folate Mass volume
in Serum Plasma or Blood

Hematocrit
White blood cell Leukocytes
volume in Blood
Glucose

Cohort3
Hemoglobin A1c Hemoglobin
total in Blood

Hematocrit
Glucose

Platelets

White blood cell Leukocytes volume in Blood

Hematocrit

Table F.7: Year 2 lab comparison
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2. Year 3
Cohort1
Urea nitrogen Mass volume
in Serum Plasma or Blood
ematocrit

Cohort2

Cohort3

Hematocrit

Hematocrit

Platelets

Hematocrit

White blood cell Leukocytes volume in Blood

Folate Mass volume
in Serum Plasma or Blood

White blood cell Leukocytes

White blood cell Leukocytes

volume in Blood

volume in Blood

Glucose

Glucose

Bilirubin total Mass volume

Hemoglobin A1c Hemoglobin total in Blood

in Serum Plasma or Blood

Hepatitis B virus surface Ab Units volume in Serum

Hepatitis B virus surface Ab Units volume in Serum

Protein Mass volume in Serum or Plasma

Urea nitrogen Mass volume
in Serum Plasma or Blood
Platelets
Protein Mass volume
in Serum or Plasma
Alkaline phosphatase Enzymatic activity
volume in Serum Plasma or Blood

Platelets
Hemoglobin A1c Hemoglobin total in Blood
Alkaline phosphatase Enzymatic

Urea nitrogen Mass volume
in Serum Plasma or Blood

Hemoglobin A1c Hemoglobin
total in Blood

Bilirubin total Mass volume
in Serum Plasma or Blood

activity volume in Serum Plasma or Blood
Protein Mass volume in Serum or Plasma
Folate Mass volume in Serum Plasma or Blood

Table F.8: Year 3 lab comparison
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Chapter F

e. Vital signs
1. Year 2

Cohort1

Cohort2

Cohort3

Heart rate

BMI

Body temperature

Blood Pressure Diastolic

Blood Pressure Diastolic

BMI

Body temperature

Blood Pressure Systolic

Heart rate

BMI

Heart rate

Blood Pressure Diastolic

Blood Pressure Systolic

Body temperature

Blood Pressure Systolic

Table F.9: Year 2 vital sign comparison

2. Year 3

Cohort1

Cohort2

Cohort3

Blood Pressure Diastolic

Body temperature

Body temperature

Heart rate

BMI

Heart rate

Blood Pressure Systolic

Heart rate

Blood Pressure Systolic

Body temperature

Body temperature

BMI

BMI

Blood Pressure Diastolic

Blood Pressure Systolic

Table F.10: Year 3 vital sign comparison
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